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ABSTRACT 
 
Susan C. Kleiman:  
Microbiome-Mediated Metabolic Activity and Weight Dysregulation in Anorexia Nervosa 
(Under the direction of Cynthia M. Bulik) 
 
 Anorexia nervosa (AN) is a serious and often life-threatening psychiatric disorder that 
continues to perplex clinicians and researchers. Treatment outcome is poor, and despite 
significant morbidity and mortality, the evidence base for treatment is weak. The biology of AN 
is poorly understood, which has hindered development of novel interventions. Compelling 
evidence that the intestinal microbiota regulates key features of AN, including weight, energy 
metabolism, anxiety, and depression, provides a strong rationale for exploring the role of this 
complex microbial community in relation to the disorder. Changes in gut microbial communities 
associated with extreme weight loss may perpetuate and contribute to AN via direct effects on 
weight and mood.  
To better understand the role of the intestinal microbiota in physiologic changes 
associated with AN, we (i) characterized the composition and diversity of the intestinal 
microbiota in acutely ill patients with AN (n=16) before and after hospital-based renourishment 
and compared with healthy controls (n=12); (ii) examined associations between microbial 
composition and diversity and measures of psychopathology in patients with AN (n=15) and 
healthy adult females (n=91); (iii) investigated changes in fecal energy content during hospital-
based renourishment and associations with the intestinal microbiota in patients with AN (n=15); 
and (iv) examined daily changes in the intestinal microbiota during hospital-based renourishment 
in patients with AN (n=3). 
 iv 
We found evidence of an intestinal microbial dysbiosis in patients with acute AN, marked 
by lower microbial diversity and taxonomic differences from healthy controls. Moreover, we 
found compositional changes to the intestinal microbiotas of patients with AN during hospital-
based renourishment, as well as relative changes in fecal energy content. Although we saw 
associations between microbial markers and psychopathology in patients with AN, there were no 
significant associations between microbial composition and diversity and psychiatric measures in 
healthy adult females.  
This work introduced a novel approach to studying the pathophysiology of AN by 
profiling the intestinal microbiota in individuals with AN using high-throughput 16S rRNA 
sequencing. Ultimately, we may identify bacterial taxa whose promotion or elimination would 
improve the efficacy and efficiency of therapeutic weight restoration, as well as the 
psychological and physical treatment experience of patients with AN. 
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CHAPTER 1  
 
GUT FEELINGS:  
A ROLE FOR THE INTESTINAL MICROBIOTA IN ANOREXIA NERVOSA?1 
 
1.1 The pathophysiology of anorexia nervosa remains unclear 
 Anorexia nervosa (AN) affects 0.9% of women and 0.3% of men in the United States(1) 
and continues to perplex clinicians and researchers. Treatment outcome is poor, especially in 
adults, and AN has the highest mortality rate of any psychiatric disorder.(2, 3) Despite 
significant morbidity and mortality,(1-4) the evidence base for the treatment of AN is weak.(5, 6) 
Although a fundamental first step in treatment, few clinical trials exist that explore how best to 
renourish individuals with AN, and treatment approaches are typically based on clinical opinion 
or guidelines.(7) Moreover, gastrointestinal effects of refeeding are uncomfortable, distressing, 
and painful, and body fat redistribution after refeeding is unequal, with disproportionate central 
adipose tissue deposition.(8) Low treatment acceptance and high treatment dropout are common. 
To date, the biology of AN and the physical adaptations that occur during weight restoration are 
poorly understood. New lenses through which to view the disorder are essential to advance 
understanding and enhance treatment. 
 Genetic epidemiological investigations indicate that AN has a strong genetic etiology.(9, 
10) Indeed, a significant familial association has been reported for AN,(11, 12) and twin studies 
estimate heritability at 48-74%.(9, 10, 13, 14) Although a strong genetic component exists, twin 
                                                
1An abbreviated version of this chapter was published as: Kleiman SC, Carroll IM, Tarantino LM, Bulik CM. Gut 
feelings: A role for the intestinal microbiota in anorexia nervosa? Int J Eat Disord. 2015 Jul;48(5):449-51. PMID: 
25639767. 
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studies clarify that environmental factors or gene environment interactions are also implicated 
and are worthy of investigation. 
 Humans coexist with numerous diverse microbial communities, or microbiotas, living in 
and on the human body. The intestinal microbiota refers to living organisms, including 
prokaryotes, eukaryotes, archaea, and viruses, while the microbiome refers to the cumulative 
genomes of these organisms. Although each person has a unique microbiota, a core set of 
microorganisms is common across individuals.(15, 16) The environment, including long-term 
dietary patterns, exerts profound influence on the intestinal microbiota.(17, 18) Short-term 
dietary changes can also induce measurable microbial shifts.(19) 
 Compelling evidence that the intestinal microbiota regulates key features of AN, 
including weight regulation, energy metabolism,(20) anxiety, and depression,(21) provides a 
strong rationale for exploring the role of this complex microbial community in the disorder. 
However, the functional role of enteric microbes in AN has never been comprehensively 
explored.(22, 23) Based on the existing literature, it is logical to posit that changes to gut 
microbial communities associated with extreme weight loss may perpetuate and contribute to AN 
via direct effects on weight and mood. Defining alterations and functional effects of AN 
intestinal microbiotas on adiposity and behavior could provide new mechanistic insights into this 
perplexing illness and guide new treatment paradigms. 
1.2 A dysbiosis or microbial imbalance in the intestinal microbiota exists in patients with 
anorexia nervosa 
 A small culture-based study of a stool sample from a single patient with AN at hospital 
admission identified 11 completely new bacterial species in the Firmicutes (n=7), Bacteroidetes 
(n=2), and Actinobacteria (n=2) phyla, which may suggest distinct characteristics of the 
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intestinal microbiota in AN.(23) However, further research is needed to investigate whether these 
new species are uniquely associated with AN. Moreover, a molecular-based study analyzing the 
intestinal microbiota of nine patients with AN found increased levels of the archaeon 
Methanobrevibacter smithii.(22) Although intriguing, this study was cross-sectional and used a 
narrow approach [quantitative polymerase chain reaction (PCR) of specific bacterial taxa] to 
determine the abundances of a limited number of microbial groups (n=4). Given that the 
intestinal microbiota encompasses 500–1,000 different microbial species,(24) a more 
comprehensive characterization of the intestinal microbiota in AN, how it changes following 
treatment, and how it differs from healthy controls is warranted. Exploration of longitudinal 
changes in the intestinal microbiota in patients with AN over the course of medically supervised 
weight restoration would provide new insights into how current AN treatment impacts enteric 
microbes and how microbial shifts may contribute to adipose distribution and behavior. 
1.3 The intestinal microbiota influences adiposity in humans and animal models 
 Consistent evidence implicates the intestinal microbiota in excessive accumulation and 
storage of fat in humans.(25, 26) Additionally, in mice, obese intestinal microbiotas are more 
effective at extracting calories from food and stimulating host accumulation of fat than 
microbiotas of lean mice.(27) Transfer of microbiotas from mouse models of diet- or genetically-
induced obesity to germ-free (GF) mice is sufficient to stimulate increased adiposity and 
metabolic dysfunction.(27) Similarly, fecal samples transplanted to mice from obese adult 
humans transmit obesity-associated phenotypes via the intestinal microbiota.(20) Given that AN 
is marked by extreme weight dysregulation and is treated initially by weight restoration,(28) 
exploring the functional impact of a dysbiotic intestinal microbiota on adiposity in AN is a 
logical and critical step toward better understanding of AN pathophysiology and treatment 
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response. 
1.4 The intestinal microbiota influences behavior in humans and animal models 
 A majority of individuals with AN report a lifetime history of comorbid anxiety disorders 
(75%)(29-31) or major depressive disorder (80%).(32) Animal models provide evidence that 
enteric microbes significantly influence both anxiety and depression, and many studies have 
documented behavioral changes following pathogenic infection or manipulation of the intestinal 
microbiota. For example, infection with a pathogenic microbe increases anxiety-like 
behavior,(33-35) and GF mice exhibit reduced anxiety-like behavior that is reversed upon 
reconstitution with a gut microbiota.(36-39) Furthermore, GF BALB/c mice colonized with an 
NIH Swiss intestinal microbiota show reduced anxiety-like behavior compared to GF NIH Swiss 
mice colonized with a BALB/c microbiota, indicating that gut microbe-associated changes in 
anxiety are transmissible and are affected by the composition of the intestinal microbiota.(40) 
Probiotics have been shown in animal models to reduce depressive and anxiety-like behavior at 
effect sizes similar to antidepressant treatment,(41, 42) and prebiotics may reduce stress-induced 
anxiety-like behavior and stimulate changes in microbial diversity.(43)  
These findings suggest that changes within the intestinal microbiota may be of central 
importance to the development or maintenance of depression and anxiety, but few studies have 
examined associations of the enteric microbe-gut-brain axis in human samples—and significant 
results generally lack replication. Two studies comparing the intestinal microbiotas of 
individuals with mild-to-severe depression to healthy controls generated mixed findings, with 
one failing to find significant between-group differences,(44) while the other found increased 
diversity in individuals with major depressive disorder and significant taxonomic 
differences.(45) Prebiotic and probiotic supplementation have also emerged in human clinical 
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studies as potential means for altering mood, with improvement in measures of depression, 
anxiety, cognitive reactivity, and stress levels in healthy volunteers after placebo-controlled 
supplementation trials of prebiotic or probiotic formulas.(46-48) However, prebiotic or probiotic 
supplementation has not always been associated with observable compositional changes to the 
intestinal microbiota.  
There are many possible physiologic mechanisms involved in the enteric microbe-gut-
brain axis. Bravo et al. (2011) suggest that a naturally occurring enteric microorganism used as a 
probiotic impacts behavior via the vagus nerve (the main gut-brain communication pathway) and 
gamma-aminobutyric acid (GABA) expression in the brain.(41) However, the intestinal 
microbiota also (i) stimulates release of cytokines and chemokines that can elicit immune 
response; (ii) synthesizes neurotransmitters and short-chain fatty acids that have neuroactive 
properties and can influence a range of other physiologic functions; and (iii) regulates 
permeability of the blood-brain barrier.(49)  
The investigation of the specific enteric microbes that influence anxiety and depression in 
AN has never been attempted. Yet the centrality of anxiety and depression in AN, and the 
demonstrated role of the intestinal microbiota on these traits, support research to identify 
whether microbial shifts in patients with AN correlate with anxiety and depression measures and 
whether they can confer anxiety and depression to GF mice. 
1.5 The intestinal microbiota is a valid intervention target 
 Studies involving transplantation of intact uncultured microbiotas from healthy humans 
to individuals with Clostridium difficile-induced colitis or patients with metabolic syndrome 
have provided proof-of-principle that the intestinal microbiota represents a valid therapeutic tool 
for treating or preventing disease.(50-52) These findings provide a basis for the of use of fecal 
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microbial transplants beyond the treatment of C. difficile and metabolic syndrome, but this 
research is in its infancy and the mechanism by which these transplants (via enema or capsule) 
induce a beneficial outcome is unclear. Supporting this concept, a probiotic originally isolated 
from the intestinal microbiota of a healthy individual (Lactobacillus rhamnosus JB-1) reduced 
anxiety- and stress-related behavior in mice via modulation of the expression of GABA in the 
brain.(53) These biological and behavioral effects were not seen in vagotomized mice, 
illustrating the critical role of microbe-gut-brain communication. Thus, an enteric microbe, 
originating from the intestinal microbiota, is known to regulate behaviors that are prominent in 
AN. Identifying microbes within the intestinal microbiota of patients with AN associated with 
specific AN traits (weight regulation, anxiety, and depression) that are transmissible to GF mice 
would provide a rationale to develop new, microbiota-based treatments for this disorder. 
 This research would pioneer the combination of large scale 16S rRNA gene sequencing-
based studies of intestinal microbiotas in AN with exploration of their functional influence on 
weight regulation and behavioral traits associated with AN. Correlating the configuration of an 
individual’s intestinal microbiota with health status is a fundamental first step in testing for a 
causative role of enteric microbes in AN. A unique challenge for this research is the inability to 
compare individuals with AN to similarly malnourished individuals who do not have AN or 
other medical conditions that result in malnutrition. This does not preclude other informative 
designs that could, for example, explore whether the presence of specific enteric microbes are 
associated with successful maintenance of therapeutically restored weight after renourishment. 
 A major challenge for current microbiome-related research is how to move from 
observational to functional and mechanistic studies that dissect how these microbes impact a 
host’s biology. One option is transplanting an intact uncultured human intestinal microbiota 
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(from feces) from patients with AN into GF mice and measuring anthropometric, metabolic, and 
behavioral changes that occur, along with the composition of the intestinal microbiota. This 
would test the ability of donor microbiotas to functionally impact AN-related phenotypes (i.e., 
weight regulation, anxiety, and depression) in the recipient animals. Identifying enteric microbes 
that have a potential detrimental or beneficial impact on weight regulation and behavior in 
patients with AN would generate target microbes that can then be studied further on a platform 
that enables the investigation of host–microbe interactions, namely gnotobiotics. 
 Novel interventions for AN are essential. Microbiota-modulating strategies could 
comprise a significant therapeutic advance in the treatment of AN. Our incomplete 
understanding of the pathophysiology of AN has hindered the development of novel, safe, 
acceptable, and effective interventions. Concerted attention to this area could identify bacterial 
taxa whose promotion or elimination would improve the efficiency of therapeutic weight 
restoration, as well as the psychological and physical treatment experience of patients. We need 
new information about the biology of AN at a microbial level to inform innovative therapies 
targeting enteric microorganisms, which may fundamentally alter the way we understand and 
treat AN.  
 As a critical first step, the overarching goal of this dissertation is to gain a greater 
understanding the role of the intestinal microbiota in the physiologic changes associated with 
AN. We hypothesize that a unique intestinal microbial dysbiosis arises from prolonged 
starvation in patients with AN. To address our knowledge gap related to the underlying biologic 
mechanisms of this disorder, my research sought to:  
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(i) Characterize the composition and diversity of the intestinal microbiota in acutely ill 
patients with AN before and after hospital-based renourishment and compared to 
healthy controls (Chapter 2);  
Hypothesis: the intestinal microbiota in patients with AN will differ in measures of 
composition and diversity from that of healthy controls and change over the course of 
hospital-based renourishment.   
(ii) Examine associations between microbial composition and diversity and measures of 
depression, anxiety, and eating disorder psychopathology in patients with AN (Chapter 
2) and healthy females (Chapter 4);  
Hypothesis: the composition and diversity of the intestinal microbiota is significantly 
associated with measures of psychopathology in patients with AN and healthy females. 
(iii) Investigate changes in fecal energy content during hospital-based renourishment and 
associations with the intestinal microbiota (Chapter 3); 
Hypothesis: the intestinal microbiota in AN, which is altered during renourishment, 
adaptively responds to a low-energy environment (i.e., prolonged caloric restriction). 
and 
(iv) Characterize daily changes in composition and diversity of the intestinal microbiota in 
three acutely ill patients with AN over the entire course of hospital-based 
renourishment and identify enteric bacterial groups associated with metabolic changes 
during treatment (Chapter 5). 
Hypothesis: changes in composition and diversity of the intestinal microbiota in 
patients with AN during hospital-based renourishment will be associated with 
metabolic changes in these patients.  
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CHAPTER 2  
 
THE INTESTINAL MICROBIOTA IN ACUTE ANOREXIA NERVOSA  
AND DURING RENOURISHMENT: RELATIONSHIP TO DEPRESSION, ANXIETY, 
AND EATING DISORDER PSYCHOPATHOLOGY2 
 
2.1 Introduction 
 The robust and documented role of the intestinal microbiota in metabolic function and 
weight regulation provides a strong rationale for exploring the role of this complex microbial 
community in the emergence, maintenance, and recovery from anorexia nervosa (AN).(26) AN 
is a severe, life-threatening mental illness(54) associated with dangerously low body weight and 
biochemical, metabolic, immunologic, and sensory abnormalities,(55-60) as well as mortality 
rates among the highest for any psychiatric disorder.(3) Despite the significant morbidity and 
mortality associated with AN(1-4) and decades of research, the evidence base for its treatment is 
weak—especially during the initial renourishment phase.(5, 61) Current models are unable to 
account for how individuals with AN can achieve and defend such low body weights. 
 The composition of the human microbiota, which includes the diverse microbial 
communities living in and on the human body, as well as the genetic material of these 
microorganisms (microbiome) and their interactions with the surrounding environment, has 
become a burgeoning area of study. The composition of these microbial communities can vary 
with age, sex, environment, geography, diet, and disease, but we understand little about the 
nature of these variations or their impact on human development, physiology, immunity, and 
                                                
2Kleiman SC, Watson HJ, Bulik-Sullivan EC, Huh EY, Tarantino LM, Bulik CM, Carroll IM. The Intestinal 
Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating 
Disorder Psychopathology. Psychosom Med. 2015 Nov-Dec;77(9):969-81. PMID: 26428446. 
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nutrition.(62) Seminal work by the Human Microbiome Project has characterized the 
microbiome in a cohort of healthy individuals,(63) whereas other investigators have focused on 
how deviations from the norm could contribute to diseases such as inflammatory bowel diseases 
(IBD),(64) asthma,(65-70) and obesity.(22, 25, 27, 71-74) 
 A growing body of evidence from both animal models and human studies shows 
communication between the intestinal microbiota and the brain (i.e., the so-called gut-brain 
axis).(75) This phenomenon has not been studied in individuals with AN, and the specific 
mechanism(s) through which enteric microbes affect brain function remains unclear. However, 
individuals with AN often present with comorbid anxiety and depression—up to 80% will 
experience major depression at some point in their lifetime,(32) whereas up to 75% will have 
some form of anxiety disorder, including social phobia, specific phobia, and generalized anxiety 
disorder.(29-31) 
 The intestinal microbiota plays a demonstrable role in weight gain/loss(22, 25, 27, 71-74) 
and energy extraction from the diet(27, 74, 76) in human and animal models. Given that AN is 
marked primarily by extreme weight dysregulation,(28) exploring the role of the intestinal 
microbiota in AN is a logical and inevitable next step. Consistent evidence implicates this enteric 
microbial community in obesity and metabolic outcomes, although the degree of that 
contribution is controversial.(20, 25, 27, 52, 73) Findings suggest that the composition of the 
intestinal microbiota differs between obese and lean individuals,(25, 73) and that obese 
individuals may extract more energy from a given diet than their lean counterparts,(27) but very 
little is known about the gut microbiota in individuals with AN. 
 Intriguing published and preliminary findings suggest a role for the intestinal microbiota 
in AN. A culture-based study of a stool sample from an AN patient at hospital admission 
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identified 11 completely new bacterial species in the Firmicutes (n=7), Bacteroidetes (n=2), and 
Actinobacteria (n=2) phyla, suggesting distinct characteristics of the gut microbiome in AN.(23) 
Further research is needed to investigate whether these new species are uniquely associated with 
AN. In addition, a molecular-based study(22) analyzing the intestinal microbiota of nine patients 
with AN found increased levels of the archaeon Methanobrevibacter smithii. Because M. smithii 
and other methanogens play an important role in removing excess hydrogen gas from the gut and 
improving efficiency of microbial fermentation (and associated energy yield), this could 
demonstrate an adaptive response toward optimizing energy extraction from a very low-calorie 
diet. Although novel findings were reported, this study analyzed a limited number of microbial 
groups (two phyla: Bacteroidetes and Firmicutes; one genus: Lactobacillus; and one archaeon: 
M. smithii). Animal models also suggest that the intestinal microbiota influences satiety 
mechanisms through interaction with peptide signaling(77) and protective adaptation in a 
starvation state.(78) A more comprehensive characterization of the intestinal microbiota of 
individuals with acute AN is required, along with exploration of changes in enteric microbes 
over the course of medically supervised weight restoration. 
 This study sought to i) gain insight into the composition and diversity of the intestinal 
microbiota in a cohort of patients with acute AN; ii) measure changes in the intestinal microbiota 
of patients with AN after hospital-based weight restoration; iii) compare the intestinal microbiota 
in acutely ill patients with AN to that of a healthy comparison group (HCG); and iv) examine 
associations between these microbial measures and depression, anxiety, and eating disorder 
psychopathology. 
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2.2 Methods and Materials 
 The study was approved by the Biomedical Institutional Review Board at the University 
of North Carolina at Chapel Hill (UNC). All participants provided written consent before study 
participation. 
 Females (n=16) admitted for inpatient treatment at the UNC Center of Excellence for 
Eating Disorders (CEED) participated in the study. Participants were recruited from consecutive 
inpatient admissions from December 2012 to May 2013, and inclusion criteria were as follows: 
a) age 15 to 64 years; b) meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition, Text Revision criteria for AN; and c) present at less than 75% of ideal body weight. 
Exclusion criteria were based on factors known to influence the composition of the intestinal 
microbiota: history of gastrointestinal tract surgery (other than appendectomy or 
cholecystectomy); history of IBD, irritable bowel syndrome, celiac disease, or any other 
diagnosis that could explain chronic or recurring bowel symptoms; treatment in the last two 
months with antibiotics, nonsteroidal anti-inflammatory drugs, or steroids; or intentional use of 
probiotics during the last two months. 
 Data from HCG (n=12) with no recurring gastrointestinal symptoms were obtained from 
a previous study.(79) This study recruited controls via advertisement from the general population 
in the same geographical region (central North Carolina) and from UNC outpatient clinics. HCG 
participants were subject to the same exclusion criteria as patients with AN and were selected for 
this analysis based on sex (female), age (15 to 64 years), and body mass index (BMI; 18.5–24.9 
kg/m2). They were not screened for psychopathology during recruitment. 
 Weight and height were assessed using a calibrated digital scale and stadiometer. HCG 
participants were measured once. AN patients were weighed daily as part of standard treatment. 
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Height was measured at admission for all AN patients and again at discharge for those younger 
than 21 years. Eating disorders diagnosis and psychopathology were established via the Eating 
Disorder Examination(80) and the Structured Clinical Interview for DSM-IV-TR Axis I 
Disorders(81) conducted by credentialed members of the CEED Assessment Core. AN patients 
also completed electronic versions of the Beck Anxiety Inventory (BAI),(82) Beck Depression 
Inventory-II (BDI),(83) and Eating Disorder Examination–Questionnaire (EDE-Q)(84) within 24 
hours of admission. 
 The first stool sample produced after admission (T1) was collected for all AN patients 
(n=16), and for a subset of these patients (n=10), an additional sample was collected before 
discharge (T2). Input and output are measured as part of routine treatment, minimizing risk of 
missing samples, and all samples were collected by nurses trained in collection protocols. Fresh 
stool samples were collected from HCG in the same manner as AN patients, as previously 
reported.(79) All samples were transferred to the laboratory, where they were mechanically 
homogenized with a sterile spatula, aliquoted into sterile 2 ml cryovials, and stored in a -80 °C 
freezer for future DNA isolation and nucleotide sequence analysis. 
 Bacterial DNA was isolated from collected samples using a phenol/chloroform extraction 
method combined with physical disruption of bacterial cells and a DNA clean-up kit (Qiagen 
DNeasy Blood and Tissue extraction kit [Qiagen, Valencia, CA]), as previously described.(79, 
85) 
 Bacterial community composition in isolated DNA samples was characterized by 
amplification of the V1-3 (forward, 8f: 5'-AGAGTTTGATCMTGGCTCAG-3'; reverse, 518r: 5'-
ATTACCGCGGCTGCTGG-3') variable region of the 16S rRNA gene by polymerase chain 
reaction (PCR), as previously described.(79) 16S rRNA PCR products were quantified, pooled, 
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and purified for the sequencing reaction. Sequencing was performed on a 454 Life Sciences 
Genome Sequencer FLX machine (Roche, Florence, SC) by the Microbiome Core Facility in the 
UNC School of Medicine. 
 16S rRNA sequence data generated by the 454 sequencer were processed by the 
Quantitative Insights Into Microbial Ecology (QIIME) pipeline.(86) Sequences that were less 
than 200 base pairs or greater than 1000 base pairs in length, contained incorrect primer 
sequences, or contained more than one ambiguous base were discarded.(87) Sequences were 
clustered into Operational Taxonomic Units (similar to species level) based on their sequence 
similarity at a 97% threshold using BLAST and assigned taxonomy using the Greengenes 
database.(88) Principal coordinates were generated using unweighted and weighted UniFrac 
distances.(89-91) The richness of the intestinal microbiota was characterized by the number of 
observed bacterial species in each sample and the Chao-1 estimator of diversity.(92, 93) 
 Differences in alpha diversity (expressed as number of observed species and Chao-1 
estimator), beta diversity (UniFrac distances), and taxa abundance of bacterial groups (at the 
phylum, class, order, family, and genus levels) were examined in AN patients (n=10) at T1 
versus T2 using 16S rRNA sequence data. Bacterial groups present in at least 25% of all samples 
at T1 or T2 were included in analyses. Because response variables were not normally distributed, 
nonparametric testing was used. Depending on the symmetry of the distribution of the paired 
differences, differences were tested at the univariate level using Wilcoxon matched-pairs rank 
test (-2 <= skewness <= 2) or the sign test (skewness <= -2 or >= 2). Power analysis was 
conducted in G*Power 3 to determine the effect size that could be detected with n=10, a two-
tailed test, an [alpha] of 0.05, and power of 80%; under these conditions, the Wilcoxon matched-
pairs rank test can detect a large effect (dz=1.1), as can the sign test (g=0.41). The false 
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discovery rate (FDR) procedure addressed multiple testing(94) and was applied to the number of 
comparisons per outcome and per taxonomic rank. A global, multivariate hypothesis test 
developed for high-dimensional small-sample data (i.e., the type of data acquired through high-
throughput technology in metabolomics, genomics, and proteomics) was also used to test for 
differences in alpha diversity, beta diversity, and taxa abundance across all bacterial groups.(95) 
A global test offers additional conceptual advantages to a univariate test because microbiota can 
work together or in a pathway and may have greater explanatory power when considered 
collectively. 
 Differences in alpha diversity, beta diversity, and taxa abundance of bacterial groups (at 
the phylum, class, order, family, and genus levels) were compared in AN patients at T1 (n=16) 
versus HCG (n=12) and AN patients at T2 (n=10) versus HCG with two-tailed Wilcoxon-Mann-
Whitney tests. The Chi et al.(95) global multivariate test was used for beta diversity and per 
taxonomic level, and FDR correction was applied as described earlier. 
 Associations between T1 psychopathology scores measured as continuous variables (BDI 
[depression], BAI [anxiety], and EDE-Q [total + subscales for Dietary Restraint, Eating Concern, 
Shape Concern, and Weight Concern]) and alpha diversity, beta diversity, and taxa abundance of 
bacterial groups (at the phylum, class, order, family, and genus levels) were examined in AN 
patients (n=15; one patient did not complete the surveys) with the tau-b correlation coefficient. 
Bacterial groups present in at least 25% of T1 samples were considered. Univariate analyses 
used the Wilcoxon-Mann-Whitney test, and the FDR procedure was used to adjust for multiple 
testing, implemented per outcome and per taxonomic rank. The global multivariate test was 
implemented for beta diversity and per taxonomic level. 
 The [alpha] level used was 0.05, but for FDR correction, a more lenient criterion of 0.1 
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was used given the exploratory nature and small sample size. All analyses were conducted in 
SAS 9.3 (Cary, NC). 
2.3 Results 
 Fecal samples were collected at T1 from female patients with AN (n=16). Average age 
was 28.0 (11.7; mean [standard deviation]) years, and mean BMI at T1 was 16.2 (1.5) kg/m2. A 
subset of patients (n=10) provided an additional sample at T2, when they had reached a mean 
BMI of 17.4 (0.9) kg/m2. Female HCG (n=12) who provided samples had a mean age of 29.8 
(11.6) years and mean BMI of 21.5 (1.9) kg/m2. Participants were predominately white (n=14 
patients with AN; n=7 HCG), with a small representation of African American participants (n=2 
patients with AN; n=1 HCG). Four HCG participants did not provide information on race. 
 At T1, patients with AN (n=15) had mean BDI and BAI scores of 26.6 (13.4) and 17.7 
(11.9), respectively, reflecting moderate depression and anxiety.(96, 97) Most patients endorsed 
at least mild levels of depression (80.0%) and anxiety (66.7%). Mean EDE-Q total scores of 3.6 
(1.8) and scores on subscales for Dietary Restraint (3.7 [1.9]), Eating Concern (3.4 [1.9]), Shape 
Concern (3.8 [1.9]), and Weight Concern (3.4 [2.1]) are consistent with other clinical samples of 
patients with AN.(98, 99) 
 From the 26 fecal samples analyzed from patients with AN, a total of 197,956 16S rRNA 
sequences with acceptable quality were obtained with an average of 7,613 reads per sample 
(range, 4,101–9,511). From the 12 fecal samples analyzed from HCG, a total of 122,461 16S 
rRNA sequences with acceptable quality were obtained with an average of 10,205 reads per 
sample (range, 5,265–15,596). Using a 97% similarity threshold, we found a total of 1,666 and 
2,020 Operational Taxonomic Units in the samples analyzed from patients with AN and HCG, 
respectively. 
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 Table 1 presents changes in bacterial composition and diversity over the course of 
inpatient weight restoration. Global tests indicated significant differences between T1 and T2 in 
beta (between-sample) diversity (p<0.001) and at the phylum (p=0.042) and genus (p=0.041) 
taxonomic levels (Figure 1). Based on unweighted UniFrac distances, three principal 
coordinates (5, 6, 10) were significantly different at hospital admission and discharge and 
remained significant at an FDR level of 0.1. The average unweighted UniFrac distances were 
significantly different between groups (p<0.0001), with T2 samples showing greater similarity to 
each other than T1 samples (Figure 2). The strongest taxonomic changes were seen in the family 
Ruminococcaceae, with significant changes in specified (Ruminococcus; p=0.002) and 
unspecified (p=0.004) subgenera. 
 We compared the intestinal microbiota in patients with AN at T1 and T2 to that of age- 
and sex-matched HCG. At both time points, the alpha (within-sample) diversity remained 
significantly lower in patients with AN versus HCG, measured as either the number of observed 
species or Chao-1 estimator (Figure 3; Tables 2 and 3). However, the bacterial composition of 
samples from patients with AN at T1 showed greater differences with HCG than samples 
collected at T2. At T1, patients with AN had greater levels of class Bacilli (p=0.007) and the 
unspecified genus in family Coriobacteriales (p<0.001) and reduced levels of class Clostridia 
(p=0.007), order Clostridiales (p=0.006), and genera Anaerostipes (p=0.003) and 
Faecalibacterium (p=0.002) versus HCG (with all differences remaining significant at an FDR 
level of 0.1; Table 2). At T2, the only one of these differences that remained significant was in 
the unspecified genus in family Coriobacteriales (p<0.001), although there were additional 
differences between patients with AN at T2 and HCG among the family Ruminococcaceae 
(p=0.002) and the genus Parabacteroides (p=0.006; Table 3). 
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 Alpha (within-sample) diversity, measured as bacterial richness or the Chao-1 estimator, 
was significantly associated with scores on the BDI and EDE-Q. Greater levels of depression 
were negatively associated with the number of observed bacterial species (p=0.026) and Chao-1 
estimator (p=0.026; Figure 4 and Table 4). Lower number of observed species was also 
associated with greater levels of eating disorder psychopathology, measured as EDE-Q total 
score (p=0.026) or scores on subscales for Shape Concern (p=0.008) and Weight Concern 
(p=0.025; Table 5). All associations remained significant at an FDR level of 0.1. 
 Significant associations were also seen between specific bacterial taxa and BDI, BAI, and 
EDE-Q scores, but none remained significant at an FDR level of 0.1. The strongest (negative) 
associations were seen with the family Ruminococcaceae (Tables 4 and 5). 
2.4 Discussion 
 In examining the composition and diversity of the intestinal microbiota in patients 
undergoing inpatient treatment of AN, we report i) changes over the course of hospital-based 
weight restoration; ii) significant differences between patients with AN and HCG; and iii) 
associations between microbial measures and depression, anxiety, and eating disorder 
psychopathology. These results extend findings from earlier, smaller studies of patients with AN 
and provide strong support for future work, including mechanistic studies of gut-brain 
interaction, to better understand the biological mechanisms at work in the risk and maintenance 
of AN. 
 Significant changes in the composition of the intestinal microbiota were seen in patients 
with AN during renourishment, particularly among genera falling under the family 
Ruminococcaceae. This family of bacteria has been associated with intestinal disorders marked 
by inflammation, including irritable bowel syndrome (IBS) and IBD.(100, 101) 
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 In comparing the intestinal microbiota of patients with AN to that of HCG, we found that 
alpha diversity was significantly lower in patients with AN both before and after inpatient weight 
restoration. Alpha diversity was also significantly associated with depression and eating disorder 
psychopathology in our patient group, with a lower number of observed bacterial species 
associated with greater depression and greater weight concern, shape concern, and overall eating 
disorder psychopathology. These results show intriguing associations and underscore findings 
across various other disease states, including IBD(64) and arthritis,(102) which have shown that 
a healthier gut is a more diverse one. Moreover, as we found greater differences in bacterial 
composition between AN and HCG before versus after hospital-based renourishment, our results 
may suggest that the intestinal microbiota is trending toward a healthier state during treatment. 
 Although there has been limited research to date into the role of the intestinal microbiota 
in AN, some parallels can be drawn to microbial changes associated with malnutrition. Studies 
have demonstrated that acute malnutrition in children is marked by an intestinal dysbiosis and 
that the malnutrition phenotype (marked by severe weight loss) can be transmitted via the 
intestinal microbiota in a gnotobiotic mouse model.(103, 104) This microbial dysbiosis may also 
interact with a nutrient-deficient diet to affect energy metabolism and cause malnourishment to 
persist.(103, 105) 
 Mounting evidence from animal studies in which the intestinal microbiota have been 
manipulated through probiotics, antibiotics, or microbial transfer to gnotobiotic mice has shown 
that behavior is associated with changes in bacterial composition and diversity.(40-42, 106-111) 
This includes models of depression and anxiety, which are common among patients with 
AN.(30, 31) However, we have little evidence supporting associations between the intestinal 
microbiota and depression or anxiety disorders in humans.(21, 44, 112) Our results, particularly 
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those showing that lower bacterial diversity is associated with greater depression and anxiety, are 
at the forefront of providing evidence for the gut-brain axis in a human population. 
 Several limitations should be taken into account when considering these results. First, we 
did not control for diet of either patients with AN or HCG. The composition of the intestinal 
microbiota is strongly influenced by long-term dietary patterns,(17, 18) and short-term dietary 
changes can also induce dramatic microbial shifts.(19) Because patients resided on an inpatient 
hospital unit, dietary intake was controlled, and all participants consumed a standard diet, with 
far less variation across individuals than what would be expected from those in a free-living 
environment. In addition, our sample size limited power to detect differences between patients 
and controls over the course of renourishment. However, we did see some significant 
compositional changes during inpatient treatment, as well as significant global changes in 
composition and diversity using a statistical method that provides greater explanatory power by 
considering the intestinal microbiota collectively. Third, all of our study participants were 
female, limiting generalizability of the results to males, who comprise approximately 10% of 
individuals with AN.(113) Given that we would be unlikely to recruit a sufficient number of 
male participants to allow testing for sex differences, we focused recruitment on females to 
maximize sample size. Lastly, we are unable to distinguish between changes to the intestinal 
microbiota that reflect weight gain versus recovery from AN, which will be important in future 
work, as BMI alone is associated with abundance of specific bacteria.(114) 
 Although genetic and neurobiological research underscores that AN is most accurately 
considered a biologically based mental illness, the neurobiology of AN remains an enigma, 
which has hindered the development of novel, safe, and effective treatments. These findings are 
an important first step in uncovering the role of the intestinal microbiota in AN. Future 
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mechanistic studies examining the impact of specific taxa on behavior and adiposity, including 
transplantation of the intestinal microbiota of patients with AN into gnotobiotic mice, will allow 
us to distinguish between microbial markers of renourishment and recovery from 
psychopathology and move us even closer to designing innovative therapies for AN targeting 
enteric microorganisms. Such studies could identify specific bacterial taxa whose promotion or 
elimination would improve the efficiency of therapeutic weight restoration, as well as the 
psychological and physical treatment experience of patients, and lead to pathophysiological-
directed therapeutic approaches for the management of AN via probiotic, prebiotic, symbiotic, or 
antibiotic means. 
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Table 1. Hospital admission (T1) vs. hospital discharge (T2): differences in microbial taxa 
and diversity measures in females with AN (n=10) 
 
Taxonomic/diversity 
level 
Classification Test 
statistic 
p FDR corrected p 
Global Tests 
Phylum  2.66 0.042  
Class  2.14 0.067  
Order  1.77 0.064  
Family  1.70 0.064  
Genus  1.74 0.041  
Beta diversity  Weighted 1.50 0.22  
Unweighted 6.07 0.0003  
Univariate Tests 
Family Eubacteriaceae -3.5 0.039 0.63 
Genus 
 
Ruminococcaceae_genus -26.5 0.004 0.10 
Oscillospira -22.5 0.020 0.34 
Ruminococcus 27.5 0.002 0.10 
Beta diversity Unweighted (PC 5)  -23.5 0.014 0.070 
Unweighted (PC 6) -21.5 0.027 0.090 
Unweighted (PC 10) 26.5 0.004 0.040 
a FDR = false discovery rate; PC = principal coordinate 
b Alpha = 0.05; FDR level = 0.1 
c A global multivariate test (95) was used to test for differences in alpha diversity, beta diversity, and abundance per taxonomic 
level. Depending on the symmetry of the distribution of the paired differences, differences were tested at the univariate level 
using Wilcoxon matched pairs rank test (-2 ≤ skewness ≤ 2) or the sign test (skewness ≤ -2 or ≥ 2).  
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Table 2. Hospital admission (T1): differences in microbial taxa and diversity measures in 
females with AN (n=16) vs. healthy comparison group (n=12) 
 
Taxonomic/diversity 
level 
Classification Test 
statistic 
p FDR corrected 
p 
Class Bacilli -2.72 0.007 0.026 
Clostridia 2.72 0.007 0.026 
Order Clostridiales 2.76 0.006 0.068 
Lactobacillales -2.25 0.024 0.15 
Family Actinomycetaceae -2.03 0.042 0.23 
Lachnospiraceae 2.02 0.043 0.23 
Porphyromonadaceae -2.60 0.009 0.14 
Ruminococcaceae 2.53 0.011 0.14 
Streptococcaceae -1.97 0.049 0.23 
Genus Anaerostipes 2.99 0.003 0.042 
Blautia 2.06 0.031 0.17 
Coribacteriales_genus -4.62 <0.0001 0.005 
Faecalibacterium 3.18 0.002 0.034 
Lachnospira 2.16 0.030 0.17 
Parabacteroides -2.60 0.009 0.10 
Ruminococcaceae_genus 2.30 0.022 0.16 
Ruminococcus 2.39 0.017 0.15 
Alpha diversity # of observed species 4.02 <0.0001  
Chao-1 estimator 3.83 0.0001  
a FDR = false discovery rate 
b Alpha = 0.05; FDR level = 0.1 
c Differences in alpha diversity, beta diversity, and taxa abundance of bacterial groups were compared with two-tailed 
Wilcoxon-Mann-Whitney tests. A global multivariate test (95) was used for alpha diversity, beta diversity, and abundance per 
taxonomic level. 
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Table 3. Hospital discharge (T2): differences in microbial taxa and diversity measures in 
females with AN (n=10) vs. healthy comparison group (n=12) 
 
Taxonomic/diversity 
level 
Classification Test 
statistic 
p FDR corrected 
p 
Phylum Bacteroidetes 2.08 0.038 0.11 
Firmicutes -2.08 0.038 0.11 
Class Bacteroidia 2.08 0.038 0.35 
Order Bacteroidales 2.08 0.038 0.42 
Family Porphyromonadaceae 2.74 0.006 0.15 
Genus Coribacteriales_genus 4.29 <0.0001 0.004 
Parabacteroides 2.74 0.006 0.065 
Ruminococcaceae_genus -3.07 0.002 0.047 
Alpha diversity # of observed species -2.80 0.005  
Chao-1 estimator -2.41 0.016  
a FDR = false discovery rate 
b Alpha = 0.05; FDR level = 0.1 
c Differences in alpha diversity, beta diversity, and taxa abundance of bacterial groups were compared with two-tailed 
Wilcoxon-Mann-Whitney tests. A global multivariate test (95) was used for alpha diversity, beta diversity, and abundance per 
taxonomic level. 
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Table 4. Hospital admission (T1): microbial taxa and diversity measures associated with 
depression and/or anxiety in females with AN (n=15) 
 
Taxonomic/diversity 
level 
Classification Behavioral 
measure 
Test 
statistic 
p FDR corrected 
p 
Class Clostridia BDI -0.394 0.042 0.50 
Order Actinomycetales BDI 0.406 0.040 0.40 
Clostridiales BDI -0.394 0.042 0.40 
Coriobacteriales BAI 0.410 0.036 0.40 
Family Actinomycetaceae BDI 0.406 0.040 0.46 
Rikenellaceae BDI -0.488 0.016 0.34 
Ruminococcaceae BDI -0.587 0.002 0.16 
BAI -0.566 0.004 0.16 
Genus Blautia BDI -0.433 0.026 0.47 
Faecalibacterium BDI -0.386 0.047 0.47 
Lachnospira BDI -0.526 0.008 0.47 
BAI -0.421 0.037 0.47 
Rikenellaceae_genus BDI -0.488 0.016 0.47 
Roseburia BDI -0.406 0.040 0.47 
BAI -0.503 0.012 0.47 
Ruminococcus BDI -0.490 0.011 0.47 
BAI -0.527 0.007 0.47 
Veillonella BDI 0.460 0.034 0.47 
Alpha diversity # of observed species BDI -0.433 0.026 0.045 
Chao-1 estimator BDI -0.433 0.026 0.090 
Beta diversity Weighted (PC 2) BDI -0.510 0.009 0.45 
BAI -0.488 0.013 0.45 
a FDR = false discovery rate; PC = principal coordinate; BDI = Beck Depression Inventory-II; BAI = Beck Anxiety 
Inventory 
b Alpha = 0.05; FDR level = 0.1 
c Associations were examined with the tau-b correlation coefficient.  
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Table 5. Hospital admission (T1): microbial taxa and diversity measures associated with 
eating disorder psychopathology in females with AN (n=15)  
 
Taxonomic/diversity 
level 
Classification Behavioral 
measure 
Test 
statistic 
p FDR 
corrected p 
Order Actinomycetales ShapeC 0.450 0.024 0.40 
WeightC 0.434 0.030 0.40 
Clostridiales EatingC -0.452 0.020 0.40 
EDEQ -0.448 0.020 0.40 
Turicibacterales EatingC -0.484 0.018 0.40 
Family Actinomycetaceae ShapeC 0.450 0.024 0.34 
WeightC 0.434 0.030 0.38 
Clostridiaceae Restraint -0.437 0.025 0.34 
Clostridiales_family WeightC -0.453 0.022 0.34 
Odoribacteraceae Restraint 0.450 0.024 0.34 
Ruminococcaceae Restraint -0.554 0.005 0.16 
EatingC -0.529 0.006 0.16 
ShapeC -0.534 0.006 0.16 
WeightC -0.579 0.003 0.16 
EDEQ -0.600 0.002 0.16 
Turicibacteraceae EatingC -0.484 0.018 0.34 
Genus Anaerostipes EatingC -0.463 0.028 0.47 
ShapeC -0.491 0.021 0.47 
WeightC -0.508 0.017 0.47 
EDEQ -0.505 0.016 0.47 
Bacteroidaceae_genus EatingC 0.449 0.030 0.47 
Clostridiales_genus WeightC -0.453 0.022 0.47 
Clostridium EatingC -0.445 0.037 0.47 
Eubacteriaceae_genus ShapeC -0.431 0.042 0.47 
Faecalibacterium EatingC -0.425 0.029 0.47 
ShapeC -0.459 0.019 0.47 
WeightC -0.394 0.046 0.47 
EDEQ -0.383 0.047 0.47 
Lachnospira ShapeC -0.510 0.011 0.47 
WeightC -0.495 0.015 0.47 
EDEQ -0.411 0.038 0.47 
Ruminococcaceae_genus 
 
EatingC -0.433 0.026 0.47 
ShapeC -0.418 0.032 0.47 
WeightC -0.422 0.032 0.47 
EDEQ -0.429 0.026 0.47 
Ruminococcus EDEQ -0.390 0.042 0.47 
Turicibacter EatingC -0.484 0.018 0.47 
Veillonella WeightC -0.512 0.020 0.47 
  
 27 
Alpha diversity # of observed species ShapeC -0.515 0.008 0.045 
WeightC -0.441 0.025 0.045 
EDEQ -0.429 0.026 0.045 
Chao-1 estimator ShapeC -0.476 0.015 0.090 
Beta diversity Weighted (PC 4) EatingC -0.394 0.042 0.83 
Unweighted (PC 1) EatingC -0.413 0.033 0.58 
ShapeC -0.437 0.025 0.58 
WeightC -0.422 0.032 0.58 
EDEQ -0.448 0.020 0.58 
a FDR = false discovery rate; PC = principal coordinate 
b EDEQ refers to the total score on the Eating Disorder Examination-Questionnaire. The following subscales are also included: 
Dietary Restraint (Restraint), Eating Concern (EatingC), Shape Concern (ShapeC), Weight Concern (WeightC) 
c Alpha = 0.05; FDR level = 0.1 
d Associations were examined with the tau-b correlation coefficient.  
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Figure 1. Heatmaps of samples from patients with AN at hospital admission (T1; n=16) and 
discharge (T2; n=10) at the (A) phylum and (B) genus taxonomic levels. Bacterial 
composition was characterized by 454 pyrosequencing of the 16S rRNA gene, and sequencing 
results were processed by the QIIME pipeline. A global, multivariate hypothesis test was used to 
test for differences in abundance across all bacterial groups at once, per taxonomic level, and 
indicated significant differences between T1 and T2 at the phylum (p=0.042) and genus 
(p=0.041) levels. Bacterial taxa are listed vertically, and samples are grouped horizontally by 
time point (T1 or T2). Greater abundance is designated by darker shading. *[Ruminococcus] 
indicates unspecified genera in the Ruminococcaceae family. AN = anorexia nervosa; QIIME = 
Quantitative Insights Into Microbial Ecology. 
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Figure 2. Principal coordinate plot of samples from patients with AN and average 
unweighted UniFrac distances at hospital admission (T1; n=16) and discharge (T2; n=10). 
Bacterial composition was characterized by 454 pyrosequencing of the 16S rRNA gene, and 
sequencing results were processed by the QIIME pipeline. (A) Based on unweighted UniFrac 
distances, three principal coordinates (PC 5, PC 6, PC 10) were significantly different at T1 
versus T2. Percentages indicate the amount of variability in the data explained by each PC. 
Samples from T1 and T2 are designated by royal blue and red dots, respectively. (B) The average 
unweighted UniFrac distances were significantly different across groups (p<0.0001), with T2 
samples showing greater similarity to each other than T1 samples. PC = principal coordinate; AN 
= anorexia nervosa; QIIME = Quantitative Insights Into Microbial Ecology. 
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Figure 3. Alpha diversity in samples from patients with AN at hospital admission (T1; 
n=16) and discharge (T2; n=10) and a healthy comparison group (n=12). Bacterial 
composition was characterized by 454 pyrosequencing of the 16S rRNA gene, and sequencing 
results were processed by the QIIME pipeline. Richness was characterized by the number of 
observed bacterial species in each sample (A) and Chao-1 estimator of diversity (B). Differences 
in alpha (within-sample) diversity were compared in AN T1 versus AN T2 versus HCG with 
two-tailed Wilcoxon-Mann-Whitney tests. At both time points (T1 and T2), the alpha diversity 
remained significantly lower in patients with AN versus HCG, measured as either the number of 
observed species or Chao-1 estimator. AN = anorexia nervosa; HCG = healthy comparison 
group; QIIME = Quantitative Insights Into Microbial Ecology. 
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Figure 4. Correlation between depression and alpha diversity in samples from patients with 
AN at hospital admission (T1). Bacterial composition was characterized by 454 
pyrosequencing of the 16S rRNA gene, and sequencing results were processed by the QIIME 
pipeline. Richness (vertical axes) was characterized by the number of observed bacterial species 
in each sample (A) and Chao-1estimator of diversity (B). AN patients (n=15; one patient did not 
complete the surveys) completed the Beck Depression Inventory-II (horizontal axes) within 24 
hours of admission. Associations between T1 psychopathology scores and alpha diversity were 
examined with the tau-b correlation coefficient. Depression was negatively associated with the 
number of observed bacterial species (p=0.026) and Chao-1 estimator (p=0.026). AN = anorexia 
nervosa; QIIME = Quantitative Insights Into Microbial Ecology.  
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CHAPTER 3 
 
ENTERIC MICROBIOME-MEDIATED DIETARY ENERGY EXTRACTION  
IN ACUTE ANOREXIA NERVOSA: A PILOT STUDY3 
 
3.1 Introduction 
 Treatment of anorexia nervosa (AN) challenges clinicians, scientists, and patients.(115) 
Variability in response to therapeutic renourishment remains largely unexplained. Speed of 
weight gain, metabolic fluctuations, physical and psychological distress, and re-loss of restored 
weight are likely influenced by unknown biological mechanisms.  
 The intestinal microbiota plays a significant role in metabolic function and weight 
regulation, and we reported an intestinal microbial dysbiosis in AN.(116) Moreover, obese mice 
may extract calories from food more efficiently than lean mice, and this “efficiency” can be 
passed to germ-free mice through fecal microbiota transplantation—causing increased adiposity 
in obese microbiota recipients, even on isocaloric diets.(27) The intestinal microbiota may 
mediate increased adiposity via dietary energy harvest. We therefore investigated the relationship 
between the intestinal microbiota and fecal energy content before and after clinical 
renourishment in AN.   
 Fecal energy content provides an indirect measure of energy absorption and proxy for 
efficiency of microbiota-mediated dietary energy extraction. Overfeeding lean volunteers leads 
to compositional changes to the intestinal microbiota and less energy lost in feces on a higher-
                                                
3Kleiman SC, Huh EY, Trillo-Ordonez Y, Bulik-Sullivan EC, Glenny EM, Fodor AA, Bulik CM, Carroll IM. 
Enteric microbiome-mediated dietary energy extraction in acute anorexia nervosa: a pilot study. Under Review.  
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calorie diet.(117) 
 Our objectives were to (i) investigate changes in fecal energy content during 
renourishment; and (ii) examine associations between fecal energy content and composition and 
diversity of the intestinal microbiota. We hypothesized that the intestinal microbiota in AN, 
which is altered during renourishment, has adaptively responded to a low-energy environment 
(i.e., prolonged calorie restriction). 
3.2 Methods 
The study was approved by the Biomedical Institutional Review Board at the University 
of North Carolina at Chapel Hill. All participants provided written consent. Female inpatients 
with AN (n=15), representing a subset of participants in a previous study,(116) consented to 
additional sample analysis. The first fecal sample after admission (T1) was collected for all 
patients, and when possible, an additional sample was collected before discharge (T2). Samples 
were mechanically homogenized, aliquoted into 2 mL cryovials, and stored in a −80°C freezer. 
To prepare samples (n=24: n=14 for T1, n=10 for T2) for bomb calorimetry, fecal matter 
from one cryovial was baked in pellet form for 48h at 60°C. Energy content was determined via 
Isoperibol Calorimeter Model 6200EA (Parr Instrument Co., Moline, IL), calibrated with 10 runs 
of benzoic acid. Each sample was weighed and placed in an oxygen bomb, which was placed in 
2000 mL distilled water inside the calorimeter. Energy content was calculated using heat 
produced by pellet combustion and corresponding water temperature rise. 
Bacterial DNA was isolated, and V1-3 variable region of the 16S rRNA gene was 
amplified by polymerase chain reaction (PCR).(116) 16S rRNA PCR products were quantified, 
pooled, and purified for sequencing on a 454 Life Sciences Genome Sequencer FLX machine 
(Roche, Florence, SC) by the UNC Microbiome Core Facility. Sequence data were processed by 
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the Quantitative Insights Into Microbial Ecology pipeline,(86) clustered into Operational 
Taxonomic Units at 97% threshold (using BLAST), and assigned taxonomy using the 
Greengenes database.(88) Microbial richness was characterized by Shannon diversity index.(118, 
119) 
Differences in energy intake (kcal/day) and fecal energy content (cal/g) associated with 
paired T1 and T2 samples (n=7) were compared with paired Student’s t-tests (alpha 0.05). Due to 
significant differences in energy intake between T1 and T2, and the association between energy 
intake and energy content of fecal samples, we normalized fecal energy content by participant 
energy intake from the day before sample collection to generate a relative measure of fecal 
energy content. We evaluated differences in fecal energy content using absolute and relative 
measures. 
Mixed linear models examined the relationship between energy content of all available 
fecal samples (n=24: n=14 for T1, n=10 for T2), Shannon diversity index, and bacterial taxa 
abundance at the phylum, class, order, family, and genus levels [(Diversity/Taxa) ~ Time + 
Calorimetry + 1/Participant]. Time (T1 vs. T2) and energy content (cal/g) were included as fixed 
variables and participant ID as a random variable, capturing variance in outcome explained by 
each parameter. False discovery rate (FDR) adjusted for multiple comparisons(94) at the 
recommended level of 0.1(120) using R.(121) 
3.3 Results 
 Participants (n=15), were female, mean age 28.0 (12.1) [mean (SD)] years, with mean 
BMI 16.3 (1.5) kg/m2 at T1. A subset of participants (n=10) provided a sample at T2, at mean 
BMI 17.4 (0.9) kg/m2 after mean length of stay 24.8 (12.7) days. Participants were Caucasian 
(n=13) and African American (n=2).  
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 Dietary records were available for n=7 participants and matched to paired fecal samples. 
Mean (SD) energy intake in these patients increased from 1557 (360) kcal/day at T1 to 2600 
(566) kcal/day at T2 over mean length of stay 30.4 (12.6) days, a significant increase (p<0.001, 
paired Student’s t-test) reflecting renourishment.  
 Mean (SD) absolute energy content of fecal samples did not differ between T1 [4586 
(620) cal/g] and T2 [4591 (500) cal/g] (p=0.98, paired Student’s t-test). When normalized by 
participant energy intake, relative energy content of fecal samples decreased significantly from 
T1 [3.1 (1.0) cal/g] to T2 [1.9 (0.7) cal/g] (p=0.002, paired Student’s t-test) (Figure 5). 
 Mixed linear models of the relation between absolute energy content of fecal samples 
(n=24) and taxa abundance and diversity of bacterial groups suggest significant but modest 
associations between phylum-level abundance and energy content for most phyla (Table 6, 
Figure 6), even after FDR correction. Shannon diversity index was significantly associated with 
fecal energy content (p=0.042; adjusted p=0.063), with higher energy content associated with 
greater microbial diversity. Associations at other taxonomic levels were not significant. 
3.4 Discussion 
We previously described an intestinal microbiota dysbiosis in acute AN marked by lower 
microbial diversity.(116) Exploring the role of this complex community in dietary energy 
extraction in these patients, we found evidence of relative but not absolute changes in fecal 
energy content when comparing T1 and T2, which were also modestly associated with microbial 
composition and diversity. This supports our hypothesis of microbial adaptation to a low-energy 
environment and suggests that changes in energy availability may impact mechanisms of dietary 
energy extraction that are mediated by the intestinal microbiota. 
The intestinal microbiota responds rapidly to environmental shifts, including dietary 
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quality, quantity, and composition.(19, 74, 117) Substantial increases in energy availability 
associated with renourishment in AN would be expected to influence composition and/or 
diversity of resident microorganisms. However, we found that absolute energy content did not 
differ between fecal samples at T1 and T2 despite increased energy intake. This finding could 
mean that microbial changes during renourishment support the physiologic need for weight 
restoration in AN by fully capturing additional energy availability for metabolic demands. 
Alternatively, the absence of a difference could reflect increased bioavailability of energy at T1 
vs. T2, with the intestinal microbiota at T1 being primed for maximum metabolic efficiency (i.e., 
extracting as much energy as possible from a low-calorie diet), yet the body is simply unable to 
take up all available energy—especially since caloric intake in the days after admission may be 
substantially higher than immediately prior to admission. This inability to fully absorb available 
energy could be linked to fasting-induced changes in the intestinal epithelium that decrease 
absorptive capacity.(122) 
When considered relative to energy intake, fecal energy content was significantly greater 
at T1 vs. T2, suggesting that relative energy content of fecal samples decreased as caloric intake 
increased. This pattern suggests that clinically renourished patients both consume and extract 
more calories from the diet at T2. This parallels a randomized cross-over trial where overfeeding 
lean males induced rapid compositional changes in the intestinal microbiota that were associated 
with relatively lower fecal energy content.(117) In addition, a cross-sectional study of AN 
reported greater abundance of archaeon Methanobrevibacter smithii compared with lean 
controls, which may signal adaptive response to a low-energy environment via increased energy 
yield from microbial fermentation.(22) Whether changes in relative fecal energy content are fully 
accounted for by energy increases, or reflect changes in composition and underlying biological 
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mechanisms of the intestinal microbiota, remains unknown. 
Mixed evidence surrounds associations between fecal energy content and microbial 
biomarkers. In our female patients with AN, greater fecal energy content was associated with 
greater microbial diversity, increased abundance of phyla Bacteroidetes and Proteobacteria, and 
decreased abundance of phyla Firmicutes and Actinobacteria. However, degree of overfeeding in 
healthy males was associated with increased relative abundance of Firmicutes and decreased 
relative abundance of Bacteroidetes.(117) Moreover, significant increases in fecal energy content 
on a high-fat diet were not associated with abundance of Firmicutes, Bacteroidetes, or 
Actinobacteria.(123)	Longitudinal studies are required to examine how changes in microbial 
composition are related to energy balance and biomarkers of metabolism. 
Limitations exist in our study. Fecal energy content is an indirect and imperfect measure 
of nutrient extraction via the intestinal microbiota, and efficiency of energy absorption in patients 
with AN may differ from healthy individuals due to other variables—e.g., gastrointestinal 
distress, gastric transit time, etc. This exploratory study was likely underpowered to examine 
associations between fecal energy content and composition of the intestinal microbiota at other 
taxonomic levels. 
 Clinical renourishment in AN induces dynamic shifts in energy intake and, thus, 
availability of energy to the intestinal microbiota. This change to the enteric environment may be 
associated with compositional changes that impact efficiency of microbiome-mediated energy 
extraction to maximize renourishment and minimize energy loss in feces. Longitudinal studies of 
energy balance in larger cohorts and investigations of functional impact of microbial changes on 
energy harvest are warranted to refine current therapies by harnessing natural mechanisms to 
improve efficiency and comfort of therapeutic renourishment. 
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Table 6. Hospital admission (T1) vs. hospital discharge (T2): associations between 
microbial taxa and diversity measures in females with AN 
 
Taxonomic level p FDR corrected p 
Firmicutes 0.020 0.063 
Proteobacteria 0.038 0.063 
Bacteroidetes 0.047 0.063 
Actinobacteria 0.053 0.063 
Verrucomicrobia 0.768 0.768 
Diversity measure p FDR corrected p 
Shannon diversity index  0.042 0.063 
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Figure 5. Fecal energy content in paired samples from individuals (n=7) during hospitalized 
treatment for AN. Differences in fecal energy content were evaluated using absolute and relative 
measures with paired Student’s t-tests. (a) Mean (SD) absolute energy content did not differ between T1 
[4586 (620) cal/g] and T2 [4591 (500) cal/g] (p=0.98). (b) Relative energy content of fecal samples 
decreased significantly from T1 [3.1 (1.0) cal/g] to T2 [1.9 (0.7) cal/g] (p=0.002). 
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Figure 6. Association between fecal energy content and intestinal microbial measures in samples 
(n=24) from individuals (n=15) during hospitalized treatment for AN. Fecal energy content was 
associated with the (a) Shannon diversity index (p=0.042; adjusted p=0.063), as well as phylum-level 
abundance of (b) Bacteroidetes (p=0.047; adjusted p=0.063) and (c) Firmicutes (p=0.020; adjusted 
p=0.063). 
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CHAPTER 4 
 
THE GUT-BRAIN AXIS IN HEALTHY FEMALES:  
LACK OF ASSOCIATION BETWEEN MICROBIAL COMPOSITION  
AND DIVERSITY AND PSYCHIATRIC MEASURES4 
 
4.1 Introduction 
Investigations conducted over the last decade have generated consensus among 
researchers that the intestinal microbiota plays a vital role in a range of physiologic processes, 
especially those related to immunologic and metabolic function. A healthy intestinal microbiota 
is also important for normal brain development and behavioral functions.(108) The enteric 
microbe-gut-brain axis has garnered increasing attention as a key, bidirectional communication 
pathway that influences mood, cognition, and behavior.(124-126) In addition to a direct 
connection via the vagus nerve, gut bacteria may interact with the brain through production of 
neurotransmitters, hormones, and other metabolites.  
Whether a dysbiosis in the intestinal microbiota plays a direct role in the pathophysiology 
of psychiatric disorders remains to be determined; however, both preclinical animal studies and 
clinical human studies are actively investigating this question. Numerous studies in animal 
models have documented behavioral changes following manipulation of the intestinal 
microbiota, including effects on behavior associated with stress,(111) anxiety,(107, 108, 110, 
127) and depression.(41, 42) Validating animal models of the enteric microbe-gut-brain axis in 
human populations has reported modest associations and has been limited by small sample sizes 
                                                
4Kleiman SC, Bulik-Sullivan EC, Glenny EM, Huh EY, Tsilimigras MCB, Fodor AA, Carroll IM, Bulik CM. The 
gut-brain axis in healthy females: Lack of association between microbial composition and diversity and psychiatric 
measures. Under Review.  
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and lack of consistency in assessment of psychiatric and microbial outcome measures. Although 
underpowered, these studies in human cohorts suggest a potential role for the intestinal 
microbiota in anxiety, depression, stress, cognitive reactivity, and eating disorders.(45-48, 116) 
Given the heightened interest in the enteric microbe-gut-brain axis and accumulating 
evidence supporting a role for the intestinal microbiota in mood and behavior, we investigated 
whether such associations would extend to healthy populations. We, therefore, examined 
associations between the composition and diversity of the intestinal microbiota and measures of 
depression, anxiety, eating disorder psychopathology, stress, and personality in a group of 
healthy adult females. 
4.2 Methods 
 
The study was approved by the Biomedical Institutional Review Board at the University 
of North Carolina at Chapel Hill (UNC). All participants provided written consent before study 
participation. 
Study Population 
Healthy adult females (n=100) ages 15-50 years with BMI 18.5–24.9 kg/m2 were 
recruited from central North Carolina via listserv announcements, targeted emails, and social 
media to serve as controls for ongoing research. Participants were recruited between July 2014 
and March 2015. Due to possible impact on the intestinal microbiota, potential participants were 
excluded for the following reasons: (i) history of gastrointestinal tract surgery (other than 
appendectomy or cholecystectomy); (ii) history of inflammatory bowel diseases, irritable bowel 
syndrome, celiac disease; (iii) history of eating disorders (anorexia nervosa, bulimia nervosa, 
binge-eating disorder); (iv) treatment in the last two months with antibiotics or steroids; (v) 
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intentional use of probiotics during the last two months (via food or supplement); and/or (vi) 
abuse of laxatives within the last month.  
Body Composition and Assessments 
Participants self-reported current height and weight during the screening process. 
Participants completed an online psychiatric questionnaire that included five widely-used and 
validated measures: (i) Beck Anxiety Inventory (BAI);(96, 128) (ii) Beck Depression Inventory-
II (BDI);(97, 129) (iii) Eating Disorder Examination-Questionnaire (EDE-Q);(130, 131) (iv) 
Perceived Stress Scale (PSS);(132, 133) and (v) Mini International Personality Item Pool (Mini 
IPIP).(134) 
Sample Collection, Processing, and Storage 
During the consent process, participants were provided with an at-home stool collection 
kit and trained in sample collection procedures. Each kit included: Styrofoam container, 
disposable collection hat, stool collection tube, biohazard bag, pair of non-latex gloves, two ice 
packs, and stool collection record sheet. Participants were instructed to return the sample (in the 
biohazard bag, with ice packs, in the Styrofoam box) to the research office within 24 hours of 
collection and to keep the sample refrigerated during any interim period. Samples were then 
immediately transferred to the laboratory, where they were mechanically homogenized with a 
sterile spatula, aliquoted into sterile 2 ml cryotubes, and stored in a −80 °C freezer for future 
DNA isolation and molecular microbiological analysis. 
DNA Isolation 
Bacterial DNA was isolated from collected samples using a phenol/chloroform extraction 
method combined with physical disruption of bacterial cells and a DNA clean-up kit (QIAmp 
DNA Stool Mini Kit [Qiagen, Valencia, CA]), as previously described.(79, 85) 
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Sequencing of 16S rRNA Genes 
Bacterial community composition in isolated DNA samples was characterized by 
amplification of the V4 variable region of the 16S rRNA gene by polymerase chain reaction 
(PCR) (forward primer 515, 5'-GA GTG CCA GCM GCC GCG GTA A-3'; reverse primer 806, 
5'-ACG GAC TAC HVG GGT WTC TAA T-3'). Generation of 16S rRNA sequences consisted 
of two separate amplifications: (1) 95°C for three minutes, then 10 cycles of 95°C for 30 
seconds, 50°C for 30 seconds, and 72°C for 30 seconds, followed by one cycle of 72°C for five 
minutes using 120 ng of fecal DNA as template, 10 µM of each 16S V4 primer, and the 
KAPA2G Robust PCR kit (Kapa Biosystems, Wilmington, MA); and (2) 95°C for three minutes, 
then 22 cycles of 95°C for 30 seconds, 50°C for 30 seconds, and 72°C for 30 seconds, followed 
by one cycle of 72°C for five minutes using 5 µL of purified PCR product from the first 
amplification as template, 10 µM of forward and reverse primers that contain Illumina MiSeq 
adaptor sequences with a 12-base error-correcting Golay barcode incorporated in the reverse 
primer, and the KAPA HiFi HotStart ReadyMix PCR kit.(135) Purification of PCR products was 
carried out after each amplification using the HighPrep PCR clean-up kit (MagBio, Lausanne, 
Switzerland) with a DynaMag-96 side magnet (Life Technologies, Carlsbad, CA). 16S rRNA 
PCR products were then quantified and pooled for sequencing. Sequencing was performed on an 
Illumina MiSeq desktop sequencer (Illumina, San Diego, CA) by the High-Throughput 
Sequencing Facility in the Carolina Center for Genome Sciences at the UNC School of 
Medicine. 
Analysis of 16S rRNA Sequences 
16S rRNA sequencing data were processed by the Quantitative Insights Into Microbial 
Ecology (QIIME) pipeline,(86) with quality filtering as previously described.(79) Forward 
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sequence reads (250 bp) were clustered into Operational Taxonomic Units based on their 
sequence similarity at a 97% threshold using BLAST and assigned taxonomy using the 
Greengenes database.(88) Principal coordinates were generated using unweighted and weighted 
UniFrac distances.(89-91) 
 Results were validated using an alternate pipeline, in which forward reads from the 16S 
rRNA sequencing data were classified with version 2.10.1 of the RDP classifier with a threshold 
of a 50% RDP score.(136) 
 Statistical significance was determined using Kendall’s tau-b correlation coefficient in 
R.(121) R scripts are available at 
https://github.com/afodor/metagenomicsTools/blob/master/src/scripts/IanNovember2015/correlat
ionsOneColumnAtATime.txt 
The diversity of the intestinal microbiota was characterized by the Shannon diversity 
index.(118, 119) 
Statistical Analysis 
Associations between psychiatric and microbial measures were examined using Kendall’s 
tau-b correlation coefficient, in conjunction with Benjamini and Hochberg’s False Discovery 
Rate (FDR) procedure to correct for multiple comparisons.(94) Psychiatric measures included: 
BAI (anxiety), BDI (depression), EDE-Q (total + subscales for dietary restraint, eating concern, 
shape concern, and weight concern), PSS (stress), and Mini IPIP (scales for extraversion, 
agreeableness, conscientiousness, neuroticism, and imagination). Microbial measures included: 
alpha diversity (Shannon diversity index) and taxa abundance of bacterial groups at the phylum, 
class, order, family, and genus levels. Linear models were additionally constructed wherein the 
first two principal coordinates were regressed against each of the psychiatric measures and other 
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participant metadata. The FDR procedure was applied to the number of comparisons per 
outcome and per taxonomic rank. The α level used was 0.05, but for FDR correction, a more 
lenient criterion of 0.1 was used.(120) All analyses were conducted in R.(121) 
4.3 Results 
 
Of 100 participants who consented to participate in the study, 94 completed the 
psychiatric questionnaires and submitted a fecal sample, of which sequencing results from 91 
samples met quality control standards for analysis. Demographic and clinical characteristics of 
the final participant sample (n=91) are shown in Table 7. In brief, the participants had a mean 
(SD) age of 29.0 (7.9) years and were within the normal or healthy weight range for adults.(137) 
On average, their scores indicate normal or minimal levels of anxiety (BAI), depression (BDI), 
and stress (PSS) and are in line with, or lower than, those of similar non-clinical samples.(128, 
138-140) Total scores on the EDE-Q and its four subscales (dietary restraint and eating, weight, 
and shape concerns) are lower than norms for U.S. college students and young adult females in 
Sweden,(99, 141) which is likely a reflection of the participant recruitment and screening 
process, which eliminated individuals with a lifetime eating disorder history.  
Following sequencing of 16S rRNA genes, we had 91 samples with complete data, after 
excluding those samples with insufficient depth of sequence reads for our downstream analysis. 
The total number of 16S rRNA sequence reads was 15,408,275, and the mean number of reads 
was 169,322 per sample (range: 47,709-317,349 sequence reads).   
When examining associations between psychiatric measures and the composition and 
diversity of the intestinal microbiota, there were no associations that met established significance 
thresholds.  We considered 17 different measures from our human participants—the 15 measures 
in Table 7 plus participant height and weight. The RDP classifier reported 261 non-rare taxa (13 
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phyla, 19 classes, 24 orders, 52 families, and 153 genera) that were present in at least 10% of our 
samples. At each taxonomic level, we also calculated the Shannon diversity index. We evaluated 
4,522 hypotheses [17 measures * (261 taxa + 5 Shannon diversity metrics)] using the non-
parametric Kendall’s tau-b test for association. Histograms of generated p-values across all 
possible associations (Figure 7) are largely uniform, suggesting that the null hypothesis of no 
association is generally supported across all taxonomic levels. Using FDR correction for all 
4,522 hypotheses, there were no significant hits even if the threshold were set to 93% FDR.   
We also used a less conservative correction, in which associations between each of the 17 
human measurements and each taxonomic level were corrected independently (for example, the 
comparisons of BDI and the 14 phyla were corrected only for the 14 phyla independent of all the 
other tests that we ran). Even using this much less stringent threshold, where we might expect 
some spurious correlations, there were no significant hits at a 5% FDR. We conclude that there is 
a striking lack of correlation between microbial community composition and the measurements 
we have gathered from our human cohort. 
To further visualize the associations in our data set, we generated principal coordinate 
plots using unweighted UniFrac distances and colored these plots by quartiles of the main 
psychiatric measures of interest (BAI, BDI, EDE-Q total, PSS) (Figure 8). These plots are based 
on the first three principal coordinates, which explain 11.5% (PC1), 5.16% (PC2), and 3.98% 
(PC3) of the variance in microbial composition. The plots do not show evidence of clustering or 
segregation based on extreme values on psychiatric measures, which further supports a lack of 
microbial markers for these psychiatric outcomes in this population. The regression of PC1 and 
PC2 against each of the psychiatric measures and other participant variables did not indicate any 
significant linear relationships after FDR correction. 
 48 
4.4 Discussion 
Our results provide evidence for a lack of association in physically and psychologically 
healthy adult females between microbial markers of gut composition and diversity and a 
collection of psychiatric measures, including anxiety, depression, eating-related thoughts and 
behaviors, stress, and personality. No associations between these measures met established 
significance thresholds in our analysis. 
Animal models suggest a role for the intestinal microbiota in anxiety, depression, and 
stress, and many animal studies have documented behavioral changes following manipulation of 
the intestinal microbiota using prebiotics, probiotics, antibiotics, infection with pathogenic 
bacteria, or microbial transfer to germ-free (GF) mice (i.e., mice raised in a sterile environment 
and lacking an intestinal microbiota). Seminal work by Sudo et al. (2004) on hypothalamic-
pituitary-adrenal axis activity showed that GF mice have exaggerated stress response when 
compared to conventionally-raised mice.(111) GF mice also have reduced anxiety-like behavior 
compared to conventional mice,(107, 108, 110, 127) which can be reversed via early-life 
colonization with intestinal bacteria.(107, 108) Anxiety-like behavior can also be increased in 
mice with pathogenic infection(142-144) or transferred between mice with a characteristic 
anxiety phenotype and non-anxious GF mice using microbial transfer.(40) Probiotic 
formulations, such as Lactobacillus rhamnosus and Bifidobacterium infantis, have been shown in 
animal models to reduce depressive and anxiety-like behavior at effect sizes similar to 
antidepressant treatment,(41, 42) and prebiotic human milk oligosaccharides may reduce stress-
induced anxiety-like behavior and stimulate changes in microbial diversity.(43) Altogether, these 
findings suggest that changes within the intestinal microbiota may be of central importance to the 
development or maintenance of depression and anxiety. 
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Few studies have examined associations of the enteric microbe-gut-brain axis in human 
samples, and significant results generally lack replication. Mixed evidence has come out of 
investigations comparing the intestinal microbiotas of individuals with depression to healthy 
controls, with one study failing to find significant between-group differences in microbial 
diversity or taxonomic composition,(44) while the other found increased diversity and significant 
taxonomic differences at the phylum, family, and genus levels.(45) In patients with acute 
anorexia nervosa, which is frequently comorbid with depression, work from our lab has shown 
that microbial diversity was both associated with depression and significantly lower than in 
healthy controls.(116) Composition and diversity of the intestinal microbiota may also be 
associated with temperament in young children, but how such links may evolve during the 
development of adult personality is unclear.(145) 
Prebiotic and probiotic supplementation have emerged in human clinical studies as 
potential means for altering mood, but connecting post-intervention changes in mood to 
differences in microbial composition or diversity is lacking. Studies have reported improvement 
in measures of depression, anxiety, cognitive reactivity, and stress levels in healthy volunteers 
after placebo-controlled supplementation trials of prebiotic or probiotic formulas,(46-48) but 
these supplements may not be associated with observable compositional changes to the intestinal 
microbiota. In fact, changes in mood or behavior may be mediated by the metatranscriptome 
(i.e., functional activity of enteric microbes) rather than the intestinal microbiota.(146) 
Nevertheless, clinical trials of novel treatments for depression based on manipulation of 
the intestinal microbiota are underway. Seminal work that used Lactobacillus rhamnosus to 
demonstrate the central importance of the enteric microbe-gut-brain axis(41) is currently being 
tested in human trials, which are investigating the effects of probiotic supplementation in healthy 
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volunteers and as an augmentation to antidepressant treatment for individuals with treatment-
resistant depression.(125) Another ongoing randomized controlled trial is examining the 
potential benefit of minocycline (a tetracycline antibiotic) treatment as an adjunctive treatment 
for individuals with moderate to severe depression.(147) Yet because these intervention studies 
use microbial strains that are not permanent members of the enteric microbiota, it is possible that 
any evidence of behavioral change is not due to changes to the intestinal microbiota but rather 
more direct mechanisms of action. 
These results should be considered in connection with several limitations. With respect to 
psychopathology, our sample was, on average, healthier than other non-clinical samples of 
young adults and had less variability on psychiatric measures than would have been expected. As 
such, restriction of range on psychiatric measures may have played a role in the lack of 
significant associations with microbial markers. In addition, our analysis focused on taxonomic 
and diversity measures of 16S rRNA sequencing data, which describes microbial composition 
but does not account for metabolic activity or functional impact of intestinal bacteria. We may 
have seen different results with RNA-seq or whole-genome metagenomic shotgun sequencing, or 
had we analyzed microbial communities from intestinal biopsies. Lastly, our sample consisted of 
adult females (age range: 15-50 years), which may differ with respect to these outcome measures 
from adult males or individuals in younger or older age brackets. 
The enteric microbe-gut-brain axis has attracted considerable attention in recent years, 
with much focus on the potential role of enteric microorganisms in the development or 
maintenance of psychiatric illness. Studies involving GF mouse models or clinical populations 
present extreme cases of psychopathology, which may not reflect microbial mechanisms in a 
healthy human population. This study was the first to examine associations between composition 
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and diversity of the intestinal microbiota and psychiatric measures in healthy individuals, and our 
results do not reveal associations between the intestinal microbiota and low levels of 
symptomatology in a healthy population. However, the role of the intestinal microbiota in the 
pathophysiology of psychiatric illness and evidence of the enteric microbe-gut-brain axis may 
only be observable in the presence of wider variability of symptom measures and more severe 
psychopathology. 
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Table 7. Demographic and clinical characteristics of participants (n=91) 
 
  Mean Standard Deviation 
Age  29.0 7.9 
BMI  21.7 1.9 
BAI  5.0 4.8 
BDI  5.2 5.9 
EDE-Q Total  0.6 0.5 
        Dietary restraint  0.4 0.6 
        Eating concern  0.2 0.2 
        Shape concern  1.1 0.8 
        Weight concern  0.7 0.8 
PSS  12.4 6.3 
Mini IPIP    
        Extraversion  12.6 4.1 
        Neuroticism  9.9 3.4 
        Agreeableness  16.5 2.6 
        Conscientiousness  15.2 2.9 
        Imagination  14.5 3.1 
BMI, body mass index; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory-II; EDE-Q, Eating Disorder Inventory-
Questionnaire; PSS, Perceived Stress Scale; Mini IPIP, Mini International Personality Item Pool. 
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Figure 7. Histograms of p-values for associations with psychiatric measures by taxonomic 
level. Associations between psychiatric and microbial measures were examined using Kendall’s 
tau-b correlation coefficient, in conjunction with Benjamini and Hochberg’s False Discovery 
Rate procedure, using data generated by the RDP classifier. Psychiatric measures included: Beck 
Anxiety Inventory, Beck Depression Inventory-II, Eating Disorder Examination-Questionnaire, 
Perceived Stress Scale, and Mini International Personality Item Pool. P-value frequencies were 
examined at each taxonomic level: (a) phylum; (b) class; (c) order; (d) family; and (e) genus. 
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Figure 8. Principal coordinate plots of psychiatric measures by quartile. Principal 
coordinates were generated using unweighted UniFrac distances from the QIIME pipeline and 
allocated to quartiles (red: top quartile; orange: middle two quartiles; blue: bottom quartile) 
based on scores from the (a) Beck Anxiety Inventory; (b) Beck Depression Inventory-II; (c) 
Eating Disorder Examination-Questionnaire; and (d) Perceived Stress Scale. Plots are based on 
the first three principal coordinates, which explain 11.5% (PC1), 5.16% (PC2), and 3.98% (PC3) 
of the variance in microbial composition, and do not cluster by quartile—supporting a lack of 
association between microbial markers and these psychiatric measures in healthy individuals. 
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CHAPTER 5 
 
DAILY CHANGES IN COMPOSITION AND DIVERSITY OF THE INTESTINAL 
MICROBIOTA IN PATIENTS WITH ANOREXIA NERVOSA: A CASE SERIES 
 
5.1 Introduction 
Anorexia nervosa (AN) is a severe, often life-threatening illness associated with 
substantial medical comorbidity and mortality rates among the highest of any psychiatric 
disorder.(115) The majority of patients with AN present with gastrointestinal (GI) symptoms, 
including abdominal distention, abdominal pain, and gastroparesis,(148, 149) and the GI-related 
effects of renourishment are uncomfortable and distressing—resulting in high treatment dropout. 
Moreover, the evidence base for therapeutic weight restoration is weak, in part because of 
inadequate understanding of the central biological mechanisms underlying AN.(115) Thus, novel 
therapeutic approaches that safely and effectively improve outcomes for this disorder are needed.  
The intestinal microbiota, which plays a role in gut motility and physiology and energy 
regulation,(150, 151) warrants investigation for improving treatment for AN. Indeed, AN is 
associated with an intestinal microbial dysbiosis marked by lower microbial diversity, distinct 
taxonomic differences compared with healthy controls, and associations with levels of 
depression and eating disorder psychopathology.(116, 152) Previously, we have documented 
changes in the intestinal microbiota in patients with acute AN between hospital admission for 
therapeutic renourishment and discharge,(116) and we now provide a more granular longitudinal 
exploration of changes over the course of treatment in this unique case series.  
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Although individual microbial signatures dominate in healthy samples, even over time 
and under controlled conditions, an intestinal microbial dysbiosis is associated with a range of 
pathologies, including gastrointestinal disorders, autoimmune disease, and psychiatric 
illness.(124, 153, 154) Whether the effects of treatment (e.g., clinical renourishment in AN) 
generate consistent response in the intestinal microbiota, or inter-individual variation 
predominates, is unknown. Therefore, this study aimed to (i) characterize daily changes in 
composition and diversity of the intestinal microbiota in three acutely ill patients with AN over 
the entire course of hospital-based renourishment (73, 58, and 34 days); and (ii) to identify 
enteric bacterial groups associated with metabolic changes during treatment. 
5.2 Methods 
The study was approved by the Biomedical Institutional Review Board at the University 
of North Carolina at Chapel Hill (UNC). All participants provided written informed consent 
before study participation, and parental permission forms and an age-appropriate assent forms 
were used for participants younger than 18 years. 
Study Population 
Females (n=3) admitted for inpatient treatment at the UNC Center of Excellence for 
Eating Disorders (CEED) participated in the study. Patients ages 15-64 years meeting DSM-5 
criteria for AN and presenting at <75% of ideal body weight were recruited from consecutive 
admissions between May and August 2015. Due to possible impact on the intestinal microbiota, 
potential participants were excluded for the following reasons: (i) history of gastrointestinal tract 
surgery (other than appendectomy or cholecystectomy); (ii) history of inflammatory bowel 
diseases, irritable bowel syndrome, celiac disease; (iii) treatment in the last two months with 
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antibiotics or steroids; (iv) intentional use of probiotics during the last two months (via food or 
supplement); and/or (v) abuse of laxatives within the last month.  
Body Composition and Assessments 
Weight and height were assessed at hospital admission using a calibrated digital scale and 
stadiometer. Participants were weighed daily (before breakfast, in a gown) as part of standard 
treatment on the inpatient eating disorders unit and three times per week (before breakfast, 
without shoes) after stepping down to the partial hospitalization program. Eating disorders 
diagnosis and psychopathology were established via the Eating Disorder Examination(80) and 
the Structured Clinical Interview for DSM-IV-TR Axis I Disorders(81) conducted by 
credentialed members of the UNC CEED Assessment Core. Energy intake was prescribed by 
registered dietitians, confirmed via clinical consensus, and in line with each participant’s target 
weight gain trajectory. 
Participant metabolic rate was measured at admission and weekly thereafter during 
hospitalized renourishment. Resting energy expenditure (kcal/day) was measured after overnight 
fast, before breakfast with the MedGem indirect calorimeter (Microlife Medical Home Solutions, 
Inc., Golden, CO). The same procedure was repeated one hour post-breakfast to measure post-
prandial resting energy expenditure and calculate diet-induced thermogenesis (as percentage 
increase over resting energy expenditure). Daily physical activity expenditure (kcal) was 
measured using the BODYMEDIA SenseWear armband (BodyMedia, Inc., Pittsburgh, PA), 
worn on the back of the upper left arm for a 24-hour period each week (with the exception of 
bathing or any other continuous contact with water). The 24-hour period commenced at the time 
of resting energy expenditure measurement. Active energy expenditure (min), defined as ≥3.0 
metabolic equivalents, was also captured by the armband. 
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Sample Collection, Processing, and Storage 
 Fecal samples were collected on a daily basis (or as frequently as possible, if less than 
daily) from all participants. Input and output are measured as part of routine treatment on the 
inpatient eating disorders unit, minimizing risk of missing samples, and all samples were 
collected by unit nurses and nursing assistants trained in collection protocols. After stepping 
down from the inpatient unit to the partial hospitalization program, participants received training 
in sample collection procedures and were provided with at-home collection kits for use on-site or 
at home. Each kit included: Styrofoam container, disposable collection hat, stool collection tube, 
biohazard bag, pair of non-latex gloves, two ice packs, and stool collection record sheet. All 
samples were refrigerated after collection and transferred within 24 hours to the laboratory, 
where they were mechanically homogenized with a sterile spatula, aliquoted into sterile 2 ml 
cryotubes, and stored in a −80 °C freezer for future DNA isolation and molecular 
microbiological analysis. 
DNA Isolation 
Bacterial DNA was isolated from collected samples using a phenol/chloroform extraction 
method combined with physical disruption of bacterial cells and a DNA clean-up kit (QIAmp 
DNA Stool Mini Kit [Qiagen, Valencia, CA]), as previously described.(79, 85) 
Sequencing of 16S rRNA Genes 
Bacterial community composition in isolated DNA samples was characterized by 
amplification of the V4 variable region of the 16S rRNA gene by polymerase chain reaction 
(PCR) (forward primer 515, 5'-GA GTG CCA GCM GCC GCG GTA A-3'; reverse primer 806, 
5'-ACG GAC TAC HVG GGT WTC TAA T-3'). Generation of 16S rRNA sequences consisted 
of two separate amplifications: (1) 95°C for three minutes, then 10 cycles of 95°C for 30 
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seconds, 50°C for 30 seconds, and 72°C for 30 seconds, followed by one cycle of 72°C for five 
minutes using 120 ng of fecal DNA as template, 10 µM of each 16S V4 primer, and the 
KAPA2G Robust PCR kit (Kapa Biosystems, Wilmington, MA); and (2) 95°C for three minutes, 
then 22 cycles of 95°C for 30 seconds, 50°C for 30 seconds, and 72°C for 30 seconds, followed 
by one cycle of 72°C for five minutes using 5 µL of purified PCR product from the first 
amplification as template, 10 µM of forward and reverse primers that contain Illumina MiSeq 
adaptor sequences with a 12-base error-correcting Golay barcode incorporated in the reverse 
primer, and the KAPA HiFi HotStart ReadyMix PCR kit.(135) Purification of PCR products was 
carried out after each amplification using the HighPrep PCR clean-up kit (MagBio, Lausanne, 
Switzerland) with a DynaMag-96 side magnet (Life Technologies, Carlsbad, CA). 16S rRNA 
PCR products were then quantified and pooled for sequencing. Sequencing was performed on an 
Illumina MiSeq desktop sequencer (Illumina, San Diego, CA) by the High-Throughput 
Sequencing Facility in the Carolina Center for Genome Sciences at the UNC School of 
Medicine. 
Analysis 
16S rRNA forward sequence reads were classified with version 2.10.1 of the RDP 
classifier with a threshold of a 50% RDP score.(136) The diversity of the intestinal microbiota 
was characterized by the Shannon diversity index.(118, 119) 
Following sequencing of 16S rRNA genes, we had 140 samples with sufficient depth of 
sequence reads for our downstream analysis. The mean number of 16S rRNA sequence reads 
was 69,967 per sample (range: 12,606-198,025 sequence reads). The RDP classifier reported 185 
non-rare taxa (7 phyla, 14 classes, 18 orders, 39 families, and 107 genera) that were present in at 
least 25% of our samples. 
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Linear models were constructed with bacterial taxa (or Shannon diversity index) 
regressed against the interaction of time (i.e., length of hospital stay, in days) and patient, 
inclusive of their main effects. Taxa abundance and diversity of bacterial groups were considered 
at the phylum, class, order, family, and genus levels. Additional models that included patient 
metadata (e.g., BMI and energy intake), in addition to a time-patient interaction, were also 
explored. Lastly, linear models were constructed to incorporate metabolic metadata of interest 
(i.e., resting energy expenditure, diet-induced thermogenesis, and active energy expenditure) in 
addition to a time-patient interaction. The FDR procedure was applied to the number of 
comparisons per outcome and per taxonomic rank. The α level used was 0.05, but for FDR 
correction, a more lenient criterion of 0.1 was used.(120) All analyses were conducted in R.(121) 
5.3 Results 
Demographic and clinical characteristics of patients are presented in Table 8. Patient A, 
age 25, was admitted at BMI 15.6 kg/m2. She provided 68 fecal samples over 73 days of 
treatment, reaching BMI 20.2 kg/m2 at discharge. Patient B, age 29, was admitted at BMI 17.6 
kg/m2. She provided 47 fecal samples over 58 days of treatment, reaching BMI 21.1 kg/m2 at 
discharge. Patient C, age 16, was admitted at age-adjusted BMI 13.7 kg/m2. She provided 33 
fecal samples over 34 days of treatment, reaching BMI 15.4 at discharge. Patients A and B were 
treated on both inpatient and partial-hospitalization units, while Patient C was only followed 
during inpatient treatment. Initial prescribed energy intake was 1000 (patient A) or 1400 kcal/day 
(patients B and C) and reached a maximum of 3200 kcal/day prior to discharge in all patients. 
Weekly metabolic indicators for participants are presented in Tables 9-11. In all patients, 
resting energy expenditure increased during treatment, and diet-induced thermogenesis reached a 
peak of 158-181% of resting energy expenditure in the second or third week of treatment, which 
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is consistent with previous reports.(155, 156) Total physical activity expenditure and active 
energy expenditure were stable during inpatient treatment but increased substantially in Patients 
A and B after transfer to the partial-hospitalization unit, likely reflecting unsanctioned increases 
in moderate-to-vigorous physical activity during time off-unit. 
In all three patients, we observed significant changes in the composition and diversity of 
the intestinal microbiota over the course of hospitalized renourishment at the phylum (n=3), class 
(n=6), order (n=11), family (n=13) and genus (n=36) levels (Figure 9), after FDR correction. In 
most cases, the magnitude and direction of change were patient-specific.  
As patient BMI and energy intake were strongly correlated with length of hospitalization 
and with each other, similar results were generated by regressing bacterial taxa and diversity 
against these variables. The high degree of correlation between these variables, and reproduction 
of results across models using each as the regressand, suggest that increases to model complexity 
by including BMI or patient energy intake terms to a time-patient interaction model would not 
yield additional significant findings. This was largely observed in our analysis, and in the small 
number of cases where significant changes occur in these more complex models, correlation 
between terms makes biologically meaningful interpretation difficult. Weekly changes in resting 
energy expenditure, diet-induced thermogenesis, and active energy expenditure were also highly 
correlated with duration of patient hospitalization. Adding these variables to the time-patient 
model did not generate any significant associations with composition or diversity of the intestinal 
microbiota. 
5.4 Discussion 
These results support earlier assertions that individuals do not share a core microbiota, 
but rather house unique microbial communities that may experience periods of both high 
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variability and relative stability over time—due to a variety of intrinsic and extrinsic factors.(19, 
157) The Human Microbiome Project underscores the high diversity of “healthy” microbiotas, 
unexplained by phenotypic differences in participants,(158) and even when controlling both 
environment and dietary intake, inter-individual differences were the predominant source of 
variation in the intestinal microbiota during two controlled feeding studies.(18, 159) The 
observation that this pattern of unique intestinal microbiotas as seen in healthy individuals also 
occurs and persists in a pathologic state associated with microbial dysbiosis is a novel outcome 
that warrants replication in other disorders associated with an intestinal microbial dysbiosis, such 
as gastrointestinal disorders or autoimmune disease. Moreover, although these results add to 
evidence of high inter-individual variability in the composition of enteric microbial communities, 
different bacteria can carry out similar metabolic functions. This could generate a similar 
functional impact from different microbial compositions, which has led researchers to posit that 
individuals may share a “core microbiome” of microbial genes that drive similar functional 
impact in the host.(160)  
Limitations exist in these data. Although a valid design for novel observations, a case 
series is limited by sample size and lack of control group. Nonetheless, these results remain an 
important contribution to understanding the biological changes associated with renourishment in 
AN patients. We may have been underpowered to detect changes in more complex longitudinal 
models, but this does not rule out the possibility that changes in microbial composition and 
diversity are associated with changes in BMI, dietary intake, or psychopathology. In measuring 
metabolic changes on a weekly, rather than daily, basis, we may have also been underpowered to 
detect associations with microbial measures, despite evidence supporting a role for the intestinal 
microbiota in metabolic function and dietary energy extraction. Lastly, our analysis focused on 
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taxonomic and diversity measures of 16S rRNA sequencing data, which describes microbial 
composition but does not account for functional impact of the intestinal microbiota. 
In examining composition and diversity of the intestinal microbiota in three patients 
undergoing treatment for acute AN, we found significant, patient-specific changes over the 
course of hospital-based renourishment. Even in a controlled hospital environment, on a stringent 
refeeding protocol, and in a disease state marked by microbial dysbiosis, individual microbial 
signatures persisted in accounting for the majority of variation in microbial composition and 
diversity. Although all three patients experienced peaks in hypermetabolism in the second or 
third week of treatment, we were unable to detect specific associations between the 
hypermetabolic state and changes in the intestinal microbiota. It will be important for future 
work to elucidate temporal changes to the intestinal microbiome during renourishment (and 
associated changes in metabolic activity), which will increase our understanding host-microbial 
dynamics during treatment and could help explain persistence of weight dysregulation and 
metabolic changes in recovered AN patients. 
  
 64 
Table 8. Demographic and clinical characteristics of patients 
 
  Patient A Patient B Patient C 
Age (years)  25 29 16 
Race  Asian Caucasian Caucasian 
BMI (kg/m2) 
Admission 15.6 17.6 13.7 
Discharge 20.2 21.1 15.4 
Length of stay (days)  73 58 34 
Number of fecal samples  68 47 33 
Energy intake  
(kcal) 
Admission 1000 1400 1400 
Discharge 3200 3200 3200 
 
  
 Table 9. Weekly metabolic indicators: Patient A 
 
Week BMI (kg/m2) 
Resting Energy 
Expenditure 
(kcal/day) 
Post-Prandial 
Resting Energy 
Expenditure 
(kcal/day) 
Diet-Induced 
Thermogenesis 
Physical 
Activity 
Expenditure 
(kcal/day) 
Active 
Energy 
Expenditure 
(kcal/day) 
1 15.6 900 1480 164% 1243 6 
2 17.1 1110 1510 136% 1316 17 
3 17.4 940 1630 173% 1391 101 
4 18.0 1050 1680 160% 1467 120 
5 18.4 1100 1590 145% 1453 36 
6* 18.6 1120 1510 135% 1671 301 
7 19.2 1330 1520 114% 1583 125 
8 19.3 1360 1450 107% 1818 387 
9 19.7 1260 1540 122% 1747 293 
10 20.0 1290 1390 108% 1674 239 
11 20.2 1140 1530 134% 1547 66 
* Transfer from inpatient to partial-hospitalization unit 
** Diet-induced thermogenesis = post-prandial resting energy expenditure / resting energy expenditure 
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 Table 10. Weekly metabolic indicators: Patient B 
 
Week BMI (kg/m2) 
Resting Energy 
Expenditure 
(kcal/day) 
Post-Prandial 
Resting Energy 
Expenditure 
(kcal/day) 
Diet-Induced 
Thermogenesis 
Physical 
Activity 
Expenditure 
(kcal/day) 
Active 
Energy 
Expenditure 
(kcal/day) 
1 17.6 1200 1350 113% 1325 0 
2 18.0 1000 1810 181% 1326 0 
3* 17.6 1450 1800 124% 1974 636 
4 18.2 1580 1810 115% 1774 384 
5 18.9 1470 2130 145% 1662 168 
6 18.4 1200 1890 158% 1684 283 
7 19.5 1450 2030 140% 1843 376 
8 19.8 1660 2370 143% 1978 446 
9 21.1 1660 2030 122% 1994 472 
* Transfer from inpatient to partial-hospitalization unit 
** Diet-induced thermogenesis = post-prandial resting energy expenditure / resting energy expenditure 
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 Table 11. Weekly metabolic indicators: Patient C 
 
Week BMI (kg/m2) 
Resting 
Energy 
Expenditure 
(kcal/day) 
Post-Prandial 
Resting Energy 
Expenditure 
(kcal/day) 
Diet-Induced 
Thermogenesis 
Physical 
Activity 
Expenditure 
(kcal/day) 
Active 
Energy 
Expenditure 
(kcal/day) 
1 13.7 990 1250 126% 1462 2 
2 14.0 870 1090 125% 1448 4 
3 14.4 840 1330 158% 1455 5 
4 15.0 1100 1310 119% 1466 8 
5 15.4 1310 1380 105% 1465 4 
** Diet-induced thermogenesis = post-prandial resting energy expenditure / resting energy expenditure 
67 
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Figure 9. Intestinal microbiotas of three AN patients during therapeutic renourishment. 
(A) Taxonomic composition: abundance of specific genera exhibit significant variability during 
the course of refeeding. (B) Microbial richness: number of observed OTUs in each fecal sample 
varies over the course of refeeding. (C) Principal coordinate analysis of unweighted UniFrac 
distances: samples significantly cluster by patient (p=0.001, analysis of similarity), suggesting 
that disease state or clinical refeeding is not sufficient to overpower the unique enteric 
microbiota composition harbored by each individual.  
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CHAPTER 6 
 
SUMMARY AND FUTURE DIRECTIONS 
 
6.1 Summary of Findings 
This dissertation investigated the role of the intestinal microbiota in the pathophysiology 
of anorexia nervosa (AN), which we hypothesized would uniquely respond to prolonged 
starvation, by (i) characterizing the composition and diversity of the intestinal microbiota in 
acutely ill patients with AN before and after hospital-based renourishment and compared with 
healthy controls; (ii) examining associations between microbial composition and diversity and 
measures of depression, anxiety, and eating disorder psychopathology in patients with AN and 
healthy females; (iii) investigating changes in fecal energy content during hospital-based 
renourishment and associations with the intestinal microbiota; and (iv) examining longitudinal 
changes in the intestinal microbiota over the entire course of hospital-based renourishment and 
associations between these changes and metabolic changes during treatment. 
Chapter 2 described an intestinal microbial dysbiosis in patients with acute AN, marked 
by lower microbial diversity and specific taxonomic differences from a healthy comparison 
group. We also found specific compositional changes to the intestinal microbiota of these 
patients over the course of hospital-based weight restoration and associations between microbial 
diversity and levels of depression and eating disorder psychopathology. This supports our 
hypothesis that the intestinal microbiota in patients with AN would differ in measures of 
composition and diversity from healthy controls, be associated with measures of 
psychopathology, and change over the course of hospital-based renourishment. AN now belongs 
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to an ever-growing list of conditions that are associated with an intestinal microbial dysbiosis 
and for which microbial mechanisms may play a role in risk, development, or maintenance of 
pathology. Understanding how the intestinal microbiota in AN differs from that of healthy 
individuals provides a stepping stone toward designing new therapies, which has been the case 
for gastrointestinal disorders such as IBD.(64) After replication of initial findings and consensus 
around the association of IBD with an intestinal microbial dysbiosis, researchers demonstrated in 
animal models of colitis that gut bacteria are necessary to bring about the disorder’s hallmark 
colonic inflammatory response. Meanwhile, fecal microbial transplantation (FMT), where an 
entire healthy intestinal microbiota is transferred via enema or capsule, emerged as a novel 
approach for altering the intestinal microbiota and was shown to be effective in treating C. 
difficile-induced colitis.(51) Thus, it was a natural progression to suggest that IBD patients could 
benefit from FMT, which has now been tested and shown to be effective in randomized clinical 
trials.(161-163) 
Moreover, finding that levels of depression, anxiety, and eating disorder psychopathology 
are associated with microbial composition and diversity introduces phenotypic targets for 
microbial therapies. One such therapy, currently undergoing evaluation for use in treatment-
refractory depression,(125) is a novel class of psychotropic medication termed psychobiotics—
live organisms that, when ingested in adequate amounts, produce health benefits in individuals 
with psychiatric illness.(164) Some of these probiotic bacteria are capable of producing 
neurotransmitters and other neuroactive substances, including GABA, serotonin, dopamine, 
norepinephrine, and acetylcholine, and their effects on the brain may be mediated via the vagus 
nerve, spinal cord, or neuroendocrine systems. Preclinical animal models have shown that 
psychobiotics may have antidepressant, anxiolytic, and anti-inflammatory effects, and clinical 
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studies of probiotic supplementation in humans have shown improvement in mood and reduction 
of anxiety and psychological distress.(124, 164) Randomized, placebo-controlled clinical trials 
of psychobiotics as treatment for depression are in progress and similar investigations are 
warranted for other psychiatric disorders, including AN, which could improve outcome via 
augmenting the intestinal microbiota.      
In the same group of patients, Chapter 3 described relative but not absolute changes in 
fecal energy content over the course of hospital-based weight restoration, as well as modest 
associations between changes in fecal energy content and phylum-level microbial composition 
and diversity. This supports our hypothesis of microbial adaptation to a low-energy environment, 
but future work will need to evaluate the biological and clinical significance of this finding. Both 
initiation of clinical refeeding in patients with acute AN and overfeeding of lean (but not obese) 
individuals resulted in a decrease in relative fecal energy content.(117) This runs counter to the 
microbial “energy extraction hypothesis,” which suggests that obese individuals are more 
efficient at extracting calories from a given amount of ingested food(27)—thus leading to lower 
fecal energy content. Given the depleted energy state in acute AN, this same “efficiency” is one 
theory for microbial adaptation, but this would imply greater energy extraction and lower fecal 
energy content prior to versus post-refeeding, which is not supported by our findings.  
Nevertheless, other factors play a role in dietary energy extraction, and may be affected 
by AN, including absorptive capacity of the intestinal epithelium. Nutrient absorption may be 
directly influenced by changes in the architecture of the intestinal epithelium (e.g., villi 
blunting/elongation or altered crypt depth) or indirectly affected by changes in intestinal 
permeability,(165) though one small study in patients with acute AN found that intestinal 
absorption was not affected either before or after therapeutic renourishment when measured by a 
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(13)C-labelled triglycerides digestion test, fecal elastase test, or d-xylose absorption test.(166) 
Mechanistic studies in GF mice that have been colonized with AN microbiotas, as well as 
biopsies of the intestinal epithelium from patients with AN, would allow investigation of changes 
to epithelial structure, epithelial cell damage, and biological markers of permeability (e.g., tight 
junction-associated proteins). Better characterization of the microbiome-mediated impact of AN 
on energy uptake may lead to therapies that manipulate microbial composition in order to 
maximize efficiency of renourishment. 
Although we saw evidence of associations between microbial markers and 
psychopathology in patients with AN, Chapter 4 showed a lack of association between 
composition and diversity of the intestinal microbiota and psychiatric measures of anxiety, 
depression, eating-related thoughts and behaviors, stress, and personality in healthy adult 
females, which did not support our hypothesis of associations between the intestinal microbiota 
and measures of psychopathology in healthy females. Nonetheless, the intestinal microbiota 
plays a critical role in normal brain development and behavioral functions,(108) and microbial 
mechanisms are an important component of gut-brain communication. Given evidence of 
microbial dysbiosis in individuals with psychiatric disorders, including major depressive disorder 
and AN,(45, 116) it may be the case that compositional changes to the intestinal microbiota only 
arise in individuals with more extreme psychopathology. However, prebiotic and probiotic 
supplementation in human clinical studies has led to improvements in measures of depression, 
anxiety, cognitive reactivity, and stress in healthy volunteers—but without observable changes to 
composition of the intestinal microbiota.(46-48) Colonization of the intestinal microbiota by 
probiotic bacteria is transient,(167) suggesting that targeting the intestinal microbiota in order to 
augment mood or behavior requires a focus on the functional impact of enteric microorganisms 
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rather than compositional changes.(146) 
Lastly, Chapter 5 highlighted patient-specific changes to the composition and diversity of 
the intestinal microbiota at all taxonomic levels over the entire course of hospital-based 
renourishment in a case series of three female patients. Although the intestinal microbiotas in 
these patients showed longitudinal changes in common taxa, the magnitude and direction of 
changes were patient-specific, and we were unable to detect significant associations between 
microbial and metabolic changes during treatment. High levels of inter-individual variability in 
microbial composition in patients with AN undergoing therapeutic renourishment mirrors 
findings from longitudinal and controlled feeding studies in healthy individuals, where individual 
differences explain the majority of microbial variability.(18, 19, 157, 159) Patient-specific 
treatment response suggests that we should focus less on the presence or absence of specific 
enteric taxa and more on enteric microbial function.  
Considering the progression of research leading to microbiota-targeted therapies for GI 
disorders, we are in the early stages of similar findings for AN. We have established that acute 
AN is associated with an intestinal microbial dysbiosis, which has been replicated in one 
additional study.(152) Mechanistic studies in GF mice will allow investigation of the specific 
effects on metabolic function and behavior from colonization with AN microbiotas. FMT may 
also prove to be a valuable therapy for cases of chronic and enduring AN, where conventional 
treatments have little efficacy, quality of life is severely impaired, and clinicians and patients 
alike are desperate for novel treatment approaches.(168) Prolonged exposure to starvation in 
chronic cases of AN may have intractable effects on the intestinal microbiota that make 
renourishment more challenging. Although speculative, by introducing a healthy, diverse 
microbial ecosystem, FMT may improve efficacy and efficiency of therapeutic renourishment 
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and minimize GI symptoms by reversing microbial dysbiosis in these patients. 
6.2 Significance and Limitations 
This dissertation has made significant contributions of the eating disorders literature by 
introducing a novel approach to studying pathophysiology of AN. We were the first to 
characterize the composition and diversity of the intestinal microbiota in acute AN using high-
throughput 16S rRNA sequencing and to examine change after weight restoration, which is a 
fundamental first step in testing for a causative role of enteric microbes in this disorder. We were 
also the first to (i) examine changes in fecal energy content during treatment for AN and the role 
of the intestinal microbiota in dietary energy extraction in this population and (ii) examine 
longitudinal changes in microbial composition and diversity over the entire course of hospital-
based treatment for acute AN and associations with metabolic markers. 
 In showing that lower bacterial diversity is associated with greater levels of depression 
and eating disorder psychopathology in patients with AN, we were at the forefront of providing 
evidence for the enteric microbe-gut-brain axis in a human population. This was followed by an 
expanded study that was the first to examine associations between composition and diversity of 
the intestinal microbiota and psychiatric measures in healthy individuals. 
 This work has initiated the profiling of the intestinal microbiota in individuals with AN, 
and we hope that by identifying the presence or absence of specific enteric microbes, it may 
become possible to identify which individuals will experience difficulties with weight restoration 
and who will succeed in maintaining therapeutically restored weight (versus relapse). Ultimately, 
we may identify specific bacterial taxa whose promotion or elimination would improve the 
efficiency of therapeutic weight restoration, as well as the psychological and physical treatment 
experience of patients with AN. 
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 These results should be considered in light of several limitations. Because this pilot work 
involved novel exploration of the role of the intestinal microbiota in AN, sample sizes were 
small, which may have limited our power to detect significant differences in microbial markers 
at the lowest taxonomic levels, between patients, over time, or in comparison to healthy controls. 
In addition, all study participants were female and between the ages of 15 and 50 years, 
reflecting the clinical population at UNC CEED. This may limit the generalizability of results to 
males, who comprise approximately 10% of individuals with AN,(113) and to those in younger 
or older age groups. 
Moreover, we did not control for dietary intake of either patients with AN or healthy 
controls in these studies. The composition of the intestinal microbiota is influenced by long-term 
dietary patterns, as well as short-term shifts in quality or quantity of food intake. This will be 
important to consider in future work, as the methodology for incorporating dietary data into 
microbiome research advances and we gain greater insight into the biological mechanisms 
through which the intestinal microbiota influences nutrient and energy extraction in patients with 
AN. 
As our work examined associations with composition and diversity of the intestinal 
microbiota in acute illness and differences in these markers between groups or over time, we are 
unable to distinguish our findings from those that reflect changes in BMI (versus recovery from 
AN), other factors that influence energy absorption (such as gastrointestinal distress and gastric 
transit time), or comorbid psychopathology (such as depression or anxiety). In addition, our 
analysis focused on taxonomic and diversity measures of 16S rRNA sequencing data, which 
describes microbial composition and diversity but does not account for metabolic activity or 
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functional impact of intestinal bacteria. Future work using GF mouse models and more advanced 
sequencing techniques will elucidate the microbial mechanisms unique to AN. 
Lastly, a unique challenge for this research is the inability to compare individuals with 
AN to similarly malnourished individuals who do not have AN or individuals with other medical 
conditions that result in malnutrition. We are limited by ethical considerations in recruiting from 
certain “control” groups and in manipulating the physiology of healthy individuals to mimic 
aspects of AN. As such, we have attempted to account for these challenges by recruiting 
individuals at a healthy weight and without current or past eating disorder psychopathology; 
however, we recognize and acknowledge that these individuals remain “imperfect” controls for 
our patient population. Ongoing work characterizing microbial dysbiosis in children suffering 
from acute malnourishment and undergoing clinical refeeding may help to distinguish microbial 
markers of weight dysregulation from those specific to behavioral features of AN.    
6.3 Future Directions 
 Research on the role of the intestinal microbiota in the emergence and maintenance of 
eating disorders is in its infancy. We have provided evidence for an intestinal microbial dysbiosis 
in AN, but how do specific microbes affect adiposity, weight regulation, and mood/behavior in 
this patient population? Future work must advance from observational to functional and 
mechanistic studies that dissect how these microbes impact host biology. This includes studies 
examining the enteric microbe-gut-brain axis in GF mice associated with AN microbiotas, which 
would allow investigating whether colonization with AN microbes induces changes in AN 
phenotypes, including weight, adiposity, and behavior. Moreover, advances in systems biology 
modeling will also allow for examining the potential metabolic impact of a defined microbial 
dysbiosis, which can be validated in human studies. In addition, investigating the role of the 
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intestinal microbiota in energy balance and gastrointestinal distress can be advanced by 
characterizing the microbial communities of the small intestine, which can be captured in 
biopsies of the intestinal mucosa. 
The ultimate goal for this line of research is to improve the efficacy and efficiency of 
treatment for AN and minimize post-renourishment relapse. It is our hope that better 
characterization of the microbial dysbiosis in patients with AN and its functional impact will lead 
to interventions that improve treatment outcomes via manipulation the intestinal microbiota, 
whether via anti-, pre-, pro-, or synbiotic supplementation or FMT. This dissertation has created 
a solid foundation for future work, which will both advance our understanding of AN and expand 
to studies of the intestinal microbiota in other eating disorders. 
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